Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2024

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to ___

Commission file number: 001-34785

XWELL, Inc.

(Exact Name of Registrant as Specified in its Charter)


Delaware		20-4988129
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

254 West 31^st Street, 11th Floor, New York, NY		10001
(Address of principal executive offices)		(Zip Code)

(Registrant’s Telephone Number, Including Area Code): (212) 750-9595

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	XWEL	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	◻	Accelerated filer	◻
Non-accelerated filer	⌧	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ⌧

As of November 14, 2024, 5,256,024 shares of the registrant’s common stock were outstanding.

Table of Contents

XWELL, Inc. and Subsidiaries

Table of Contents

		Page
PART I. FINANCIAL INFORMATION		3

Item 1.	Condensed Consolidated Financial Statements (Unaudited)	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	24
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	31
Item 4.	Controls and Procedures	31

PART II. OTHER INFORMATION		32

Item 1.	Legal Proceedings	32
Item 1A.	Risk Factors	33
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	33
Item 3.	Defaults Upon Senior Securities	33
Item 4.	Mine Safety Disclosures	33
Item 5.	Other Information	33
Item 6.	Exhibits	34

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1.Condensed Consolidated Financial Statements (Unaudited)

XWELL, Inc. and Subsidiaries

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)


	September 30,		December 31,
	2024		2023
	(Unaudited)
Current assets
Cash and cash equivalents	$	4,365	$	8,437
Marketable securities		11,660		14,613
Accounts receivable		914		1,667
Inventory		669		900
Other current assets		1,905		949
Total current assets		19,513		26,566

Restricted cash		751		751
Property and equipment, net		2,959		2,454
Intangible assets, net		1,107		1,353
Operating lease right of use assets, net		6,234		4,656
Goodwill		1,389		1,371
Other assets		1,832		1,842
Total assets	$	33,785	$	38,993

Current liabilities
Accounts payable	$	2,704	$	1,099
Accrued expenses and other current liabilities		3,692		4,968
Current portion of operating lease liabilities		2,508		2,402
Deferred revenue		946		861
Total current liabilities		9,850		9,330

Long-term liabilities
Operating lease liabilities		9,108		8,692
Total liabilities		18,958		18,022
Commitments and contingencies (see Note 13)

Equity
Common Stock, $0.01 par value per share, 150,000,000 shares authorized; 5,256,024 and 4,179,631 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively		53		42
Additional paid-in capital		473,773		470,737
Accumulated deficit		(465,111)		(455,853)
Accumulated other comprehensive loss		(2,411)		(1,924)
Total equity attributable to XWELL, Inc.		6,304		13,002
Noncontrolling interests		8,523		7,969
Total equity		14,827		20,971
Total liabilities and equity	$	33,785	$	38,993

The accompanying notes form an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

XWELL, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In thousands, except share and per share data)


	Three months ended September 30,				Nine months ended September 30,
	2024		2023		2024		2023

Revenue, net
Services	$	7,486	$	6,721	$	23,924	$	20,662
Products		936		747		2,506		2,044
Total revenue, net		8,422		7,468		26,430		22,706

Cost of sales
Labor		4,426		4,462		13,235		13,609
Occupancy		919		1,063		2,564		3,237
Products and other operating costs		1,024		852		2,834		3,057
Total cost of sales		6,369		6,377		18,633		19,903

Gross Profit	$	2,053	$	1,091	$	7,797	$	2,803

Depreciation and amortization		252		590		705		1,770
Impairment of long-lived assets		-		7,878		652		7,878
Impairment of operating lease right-of-use assets		-		517		-		517
Loss on disposal of assets		152		16		171		34
General and administrative		4,525		3,001		9,682		10,282
Salaries and benefits		1,893		1,178		5,627		5,423
Total operating expenses		6,822		13,180		16,837		25,904
Operating loss		(4,769)		(12,089)		(9,040)		(23,101)
Interest income, net		100		105		308		334
Gain on investments, realized and unrealized		106		205		293		650
Foreign exchange gain (loss)		(69)		366		(210)		(690)
Other non-operating expense, net		(73)		(178)		(205)		(292)
Loss before income taxes		(4,705)		(11,591)		(8,854)		(23,099)
Income tax expense		-		-		-		-
Net loss		(4,705)		(11,591)		(8,854)		(23,099)
Net loss (income) attributable to noncontrolling interests		(45)		60		(404)		329
Net loss attributable to XWELL, Inc.	$	(4,750)	$	(11,531)	$	(9,258)	$	(22,770)

Net loss	$	(4,705)	$	(11,591)	$	(8,854)	$	(23,099)
Other comprehensive loss from operations		(247)		(514)		(487)		(1,108)
Comprehensive loss	$	(4,952)	$	(12,105)	$	(9,341)	$	(24,207)
Loss per share
Basic and diluted loss per share	$	(0.99)	$	(2.76)	$	(2.11)	$	(5.46)
Weighted-average number of shares outstanding during the period
Basic and diluted		4,818,681		4,173,894		4,394,106		4,170,629

The accompanying notes form an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

XWELL, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

(Unaudited)

(In thousands, except share and per share data)


								Accumulated
				Additional				other		Total		Non-
	Common stock			paid-		Accumulated		comprehensive		Company		controlling		Total
	Shares	Amount		in capital		deficit		loss		equity		interests		equity
December 31, 2023	4,179,631	$	42	$	470,737	$	(455,853)	$	(1,924)	$	13,002	$	7,969	$	20,971
Issuance of restricted stock units	2,986		—		—		—		—		—		—		—
Stock-based compensation	—		—		259		—		—		259		23		282
Net loss for the period	—		—		—		(2,512)		—		(2,512)		154		(2,358)
Foreign currency translation	—		—		—		—		(175)		(175)		45		(130)
March 31, 2024	4,182,617	$	42	$	470,996	$	(458,365)	$	(2,099)	$	10,574	$	8,191	$	18,765
Issuance of restricted stock units	818		—		—		—		—		—		—		—
Exercise of stock options	3,000		—		4		—		—		4		—		4
Stock-based compensation	—		—		281		—		—		281		23		304
Net loss for the period	—		—		—		(1,996)		—		(1,996)		205		(1,791)
Foreign currency translation	—		—		—				(65)		(65)		11		(54)
June 30, 2024	4,186,435	$	42	$	471,281	$	(460,361)	$	(2,164)	$	8,798	$	8,430	$	17,228
Issuance of restricted stock units	884		—		—		—		—		—		—		—
Exercise of stock options	—		—		—		—		—		—		—		—
Stock issued related to legal settlement	416,000		4		936		—		—		940		—		940
Stock-based compensation	—		—		208		—		—		208		24		232
Proceeds from registered offering	652,705		7		1,348		—		—		1,355		—		1,355
Net loss for the period	—		—		—		(4,750)		—		(4,750)		45		(4,705)
Foreign currency translation	—		—		—		—		(247)		(247)		24		(223)
September 30, 2024	5,256,024	$	53	$	473,773	$	(465,111)	$	(2,411)	$	6,304	$	8,523	$	14,827

The accompanying notes form an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

XWELL, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) (Continued)

(Unaudited)

(In thousands, except share and per share data)


								Accumulated
				Additional				other		Total		Non-
	Common stock*			paid-		Accumulated		comprehensive		Company		controlling		Total
	Shares	Amount		in capital		deficit		loss		equity		interests		equity
December 31, 2022	4,161,613	$	42	$	468,530	$	(428,112)	$	(534)	$	39,926	$	8,023	$	47,949
Issuance of restricted stock units	6,015		—		—		—		—		—		—		—
Value of shares withheld to fund payroll taxes	—		—		(22)		—		—		(22)		—		(22)
Stock-based compensation	—		—		589		—		—		589		23		612
Net loss for the period	—		—		—		(5,509)		—		(5,509)		(320)		(5,829)
Foreign currency translation	—		—		—		—		(130)		(130)		11		(119)
March 31, 2023	4,167,628	$	42	$	469,097	$	(433,621)	$	(664)	$	34,854	$	7,737	$	42,591
Issuance of restricted stock	3,297		—		—		—		—		—		—		—
Stock-based compensation	—		—		603		—		—		603		23		626
Distributions to noncontrolling interests	—		—		—		—		—		—		(120)		(120)
Foreign currency translation	—		—		—		—		(464)		(464)		46		(418)
Net loss for the period	—		—		—		(5,730)		—		(5,730)		51		(5,679)
June 30, 2023	4,170,925	$	42	$	469,700	$	(439,351)	$	(1,128)	$	29,263	$	7,737	$	37,000
Issuance of restricted stock	3,456		—		—		—		—		—		—		—
Stock-based compensation	—		—		567		—		—		567		24		591
Grant of stock for services	—		—		3		—		—		3		—		3
Distributions to noncontrolling interests	—		—		—		—		—		—		150		150
Foreign currency translation	—		—		—		—		(514)		(514)		18		(496)
Net loss for the period	—		—		—		(11,531)		—		(11,531)		(60)		(11,591)
September 30, 2023	4,174,381	$	42	$	470,270	$	(450,882)	$	(1,642)	$	17,788	$	7,869	$	25,657

*Adjusted to reflect the impact of the 1:20 reverse stock split that became effective on September 28, 2023.

The accompanying notes form an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

XWELL, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)


	Nine months ended September 30,
	2024		2023
Cash flows from operating activities
Net loss	$	(8,854)	$	(23,099)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		705		1,770
Impairment/loss on disposal of fixed assets		569		8,429
Impairment of operating lease right-of-use assets		254		—
Unrealized gain on marketable securities		(301)		(668)
Gain on Lease Termination		(655)		(821)
Foreign currency remeasurement loss		210		690
Amortization of operating lease right of use asset		928		1,163
Stock-based compensation		818		1,832
(Gain) loss on equity investment		8		53
Changes in assets and liabilities:
Decrease in inventory		231		192
Decrease in accounts receivable		746		1,665
(Increase) in other assets, current and non-current		(1,233)		(336)
Increase (decrease) in deferred revenue		85		(266)
(Decrease) in other liabilities, current and non-current		(2,143)		(3,226)
Increase (decrease) in accounts payable		1,091		(251)
Net cash used in operating activities		(7,541)		(12,873)
Cash flows from investing activities
Acquisition of property and equipment		(1,054)		(1,639)
Investment in marketable securities		(238)		(1,991)
Acquisition of Naples Wax net of cash assumed		—		(1,574)
Sale of marketable securities		3,492		4,500
Acquisition of intangibles		(9)		(468)
Net cash provided by (used in) investing activities		2,191		(1,172)
Cash flows from financing activities
Contributions from noncontrolling interests		—		150
Net proceeds from stock sale		1,355		—
Payments for shares withheld on vesting		—		(22)
Stock options exercised		4		—
Distributions to noncontrolling interests		—		(120)
Net cash provided by financing activities		1,359		8
Effect of exchange rate changes on cash, cash equivalents and restricted cash		(81)		(174)
Decrease in cash, cash equivalents and restricted cash		(4,072)		(14,211)
Cash, cash equivalents, and restricted cash at beginning of the period		9,188		19,789
Cash, cash equivalents, and restricted cash at end of the period	$	5,116	$	5,578
Cash paid for
Income taxes	$	36	$	142
Non-cash investing and financing transactions
Issuance of shares of Common Stock for legal settlement		940		—
Capital expenditures included in Accounts payable, accrued expenses and other current liabilities	$	521	$	197

The accompanying notes form an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

XWELL, Inc. and Subsidiaries

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(In thousands, except for share and per share data)

Note 1. Business, Basis of Presentation and Liquidity

Overview

XWELL is a global wellness company operating multiple brands and focused on bringing restorative, regenerative and reinvigorating products and services to travelers. XWELL currently has four reportable operating segments: XpresSpa®, XpresTest®, Naples Wax Center and Treat™.

On October 25, 2022, the Company changed its name to XWELL, Inc. (“XWELL” or the “Company”) from XpresSpa Group, Inc. The Company’s common stock, par value $0.01 per share, which had previously been listed under the trading symbol “XSPA” on the Nasdaq Capital Market, now trades under the trading symbol “XWEL”. The Company filed an amended and restated certificate of incorporation with the Delaware Secretary of State on October 24, 2022 (the “Amended and Restated Certificate”) reflecting the name change. Rebranding to XWELL aligned the Company’s corporate strategy to build a pure-play wellness services company, in both the airport and off-airport marketplaces.

XpresSpa

XWELL’s subsidiary, XpresSpa Holdings, LLC (“XpresSpa”) has been a global airport retailer of spa services through its XpresSpa spa locations, offering travelers premium spa services, including massage, nail and skin care, as well as spa and travel products.

As of September 30, 2024, there were 19 domestic XpresSpa locations in total, 17 Company-owned locations and two franchises. The Company also had 10 international locations operating as of September 30, 2024, including two XpresSpa locations in Dubai International Airport in the United Arab Emirates, one XpresSpa location in Zayad International Airport in Abu Dhabi, UAE, three XpresSpa locations in Schiphol Amsterdam Airport in the Netherlands and four XpresSpa locations in the Istanbul Airport in Turkey.

XpresTest

The Company, in partnership with certain COVID-19 testing partners, successfully launched its XpresCheck Wellness Centers, in June of 2020, through its XpresTest, Inc. subsidiary (“XpresTest”), which offered COVID-19 and other medical diagnostic testing services to the traveling public, as well as airline, airport and concessionaire employees, and TSA and U.S. Customs and Border Protection agents during the pandemic. During 2022 and 2023, as countries continued to relax their testing requirements resulting in rapid decline of testing volumes at the Company’s XpresCheck Wellness locations, the Company started to close XpresCheck Wellness Centers. As of December 31, 2023, we have closed all XpresCheck Wellness locations.

XpresTest, Inc began conducting bio surveillance monitoring with the Centers for Disease Control and Prevention (CDC) in collaboration with Concentric by Ginkgo BioWorks in 2021. The program was extended in January 2022 and renewed in August of 2022 and 2023. In March 2024, the program funding and scope were expanded. The program was renewed in August of 2024.

HyperPointe

XWELL’s subsidiary, gcg Connect, LLC, operating as HyperPointe, provides direct to business marketing support across a number of health and health-related channels. From the creation of marketing campaigns for the pharmaceutical industry, to learning management systems to website and health related content creation, HyperPointe is a complementary service provider to XWELL’s health-focused brands as well as providing the majority of services to the external community.

Table of Contents

For reporting purposes, the former HyperPointe segment has been consolidated into the XpresTest segment.

Treat

Treat, which is operating through XWELL’s subsidiary Treat, Inc. (“Treat”) is a wellness brand that provides access to wellness services for travelers at on-site centers (currently located in JFK International Airport). In April 2024, the decision was made to close the location in the Salt Lake City International Airport.

Treat offers a full retail product offering and a suite of wellness and spa services. Travelers can purchase time blocks to use our wellness rooms to engage in interactive services like self-guided yoga, meditation and low impact weight exercises or to relax and unplug from the hectic pace of the airport and renew themselves before or after their trip.

Naples Wax Center

XWELL’s subsidiary Naples Wax, LLC, d/b/a Naples Wax Centers (“Naples Wax Center” or “Naples Wax”) which was acquired on September 12, 2023, for a purchase price of $1,624 operates three high-performing locations with core products and service offerings from face and body waxing to a range of skincare and cosmetic products. The acquisition of Naples Wax Center is intended to enable the Company to move beyond its airport client base with a business that can be adapted to a larger wellness platform while also growing its retail footprint to serve long-term financial goals.

XWELL Studios

The Company plans to open its first XWELL Studios location in Jacksonville, Florida in 2025. XWELL Studios is an out-of-airport concept providing leased space to established wellness service providers. Revenue will be derived from both lease payments received from the wellness practitioners and the sale of retail at the wellness center.

Basis of Presentation and Principles of Consolidation

The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8-03 of Regulation S-X and should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as amended. The consolidated balance sheet as of December 31, 2023 was derived from the audited annual financial statements but does not include all information required by GAAP for annual financial statements. The financial statements include the accounts of the Company, all entities that are wholly owned by the Company, and all entities in which the Company has a controlling financial interest. All adjustments that, in the opinion of management, are necessary for a fair presentation for the periods presented have been reflected by the Company. Such adjustments are of a normal, recurring nature. The results of operations for the three and nine months ended September 30, 2024, are not necessarily indicative of the results that may be expected for the entire fiscal year or for any other interim period. All significant intercompany balances and transactions have been eliminated in consolidation.

Reverse Stock Split

On September 28, 2023, the Company effected a 1-for-20 reverse stock split (the “Reverse Stock Split”) whereby every twenty shares of its Common Stock were reduced to one share of its Common Stock and the price per share of its Common Stock was multiplied by 20. All references to shares and per share amounts have been adjusted to reflect the Reverse Stock Split.

Table of Contents

Liquidity and Financial Condition

As of September 30, 2024, the Company had cash and cash equivalents of $4,365 (excluding restricted cash), $11,660 in marketable securities, and total current assets of $19,513. The Company’s total current liabilities balance, which includes accounts payable, deferred revenue, accrued expenses, and operating lease liabilities was $9,850 as of September 30, 2024, and $9,330 as of December 31, 2023. The working capital surplus was $9,663 as of September 30, 2024, compared to a working capital surplus of $17,236 as of December 31, 2023.

The Company has significantly reduced operating and overhead expenses, while it continues to focus on returning to overall profitability.

The Company has taken actions to improve its overall cash position, right sizing its corporate structure and streamlining its operations. The Company is pursuing strategic partnerships that the Company expects will further strengthen the long-term profitability of the business.

Note 2. Accounting and Reporting Policies

Use of estimates

The preparation of the accompanying unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses for the periods presented. Actual results may differ from such estimates. Significant items subject to such estimates and assumptions include the Company’s long-lived assets, intangibles assets, the useful lives of the Company’s intangible assets, the valuation of stock-based compensation, deferred tax assets and liabilities, income tax uncertainties, and other contingencies.

Revenue Recognition Policy

XpresSpa, Treat and Naples Wax Center

The Company recognizes revenue from the sale of products and services when the services are rendered at XpresSpa, Treat, and Naples Wax Centers locations and from the sale of products at the time products are purchased at the Company’s stores or online usually by credit card, net of discounts and applicable sales taxes. Accordingly, the Company recognizes revenue for the Company’s single performance obligation related to both in-store and online sales at the point at which the service has been performed or the control of the merchandise has passed to the customer. The Company recognizes revenue from Priority Pass services when an invoice is generated to Priority Pass detailing the number of services performed multiplied by the agreed upon price.

XpresTest

During the third quarter of 2022, XpresTest, in partnership with Ginkgo BioWorks in continuation of their support to the CDC’s traveler-based SARS-CoV-2 genomic surveillance program was awarded a new contract. The partnership is expected to support public health and biosecurity services totaling approximately $16,000, with an overall potential to exceed $61,000 based on CDC program options and public health priorities. As COVID-19 sub-variants and other biological threats continue to emerge, the partners plan to expand the program footprint and incorporate innovative modalities and offerings, such as monitoring of wastewater from aircraft lavatories. The current contract with Ginkgo BioWorks related to the above partnership contains fixed pricing for which the Company is entitled to $14,730 for the sample collection (passenger and aircraft wastewater) and $370 for the traveler enrollment initiatives, which represents the amount of consideration that we are entitled. The Company recognizes revenue over time for both sample collection performance obligations, using the input method based on time elapsed to measure progress towards satisfying each of the performance obligations. We recognized the revenue for the traveler enrollment initiative performance obligation in the second quarter of 2023. The Company recognizes revenue ratably (straight line basis) over the term of the contract (one year). The Company recorded $2,542 and $9,289 in revenue for the three and nine months ended September 30, 2024,

Table of Contents

respectively, and $1,603 and $5,531 in revenue for the three and nine months ended September 30, 2023, respectively related to sample collection performance obligations because the Company’s efforts towards satisfying each of the performance obligations are expended evenly throughout the period of performance.

HyperPointe

The Company’s HyperPointe business provides a broad range of service and support options for HyperPointe’s customers, including technical support services and advanced services. Technical support services represent the majority of these offerings which are distinct performance obligations that are satisfied over time with revenue recognized ratably over the contract term. Advanced services are distinct performance obligations that are satisfied over time with revenue recognized as services are delivered. Revenues billed in advance are treated as deferred revenue, which was $112 and $72 as of September 30, 2024, and December 31, 2023, respectively. Deferred revenue recognized in the three and nine months ended September 30, 2024, were $0 and $72, respectively. Deferred revenue recognized in the three and nine months ended September 30, 2023, were $111 and $321, respectively.

The Company excludes all sales taxes assessed to our customers from revenue. Sales taxes assessed on revenues are included in Accrued expenses and other current liabilities on the Company’s condensed consolidated balance sheets until remitted to state agencies.

Gift cards, customer rewards and prepaid packages

XWELL offers no-fee, non-expiring gift cards to its customers. No revenue is recognized upon the issuance of a gift card and a liability is established for the gift card’s cash value. The liability is relieved, and revenue is recognized upon redemption by the customer. As the gift cards have no expiration date, there is no provision for the reduction in the value of unused card balances.

In addition, XWELL maintains a rewards program in which customers earn loyalty points, which can be redeemed for future services. Loyalty points are rewarded upon joining the loyalty program, for customer birthdays, and based upon customer spending. When a customer redeems loyalty points, the Company recognizes revenue for the redeemed cash value and reduces the related loyalty program liability. In 2023, the Company adopted a formal expiration policy whereby any loyalty members with inactivity for an 18-month period will forfeit any unused loyalty rewards.

The costs associated with gift cards and reward points are accrued as the rewards are earned by the cardholder and are included in Accrued expenses and other current liabilities in the condensed consolidated balance sheets until used.

Naples Wax Center offers prepaid wax packages that are either unlimited for one year or a set number of services. When the packages are purchased, the sales are recorded as deferred revenue. As services related to prepaid packages are used, revenue is recognized as income. The deferred revenue as of September 30, 2024, was $828 and for the year ended December 31, 2023, deferred revenue was $778.

Translation into United States dollars

The Company conducts certain transactions in foreign currencies, which are recorded at the exchange rate as of the transaction date. All exchange gains and losses occurring from the remeasurement of monetary balance sheet items denominated in non-dollar currencies are deemed non-operating income in the condensed consolidated statements of operations and comprehensive loss. During the three and nine months ended September 30, 2024, the Company recorded $69 and $210, respectively, in exchange gains occurring from the remeasurement of monetary balance sheet items denominated in non-dollar currencies. During the three and nine months ended September 30, 2023, the Company recorded $366 in exchange losses and $690 in exchange gains respectively, occurring from the remeasurement of monetary balance sheet items denominated in non-dollar currencies.

Accounts of the foreign subsidiaries of XpresSpa are translated into United States dollars. Assets and liabilities have been translated primarily at period end exchange rates and revenues and expenses have been translated at average monthly rates

Table of Contents

for the three and nine months ended September 30, 2024. The translation adjustments arising from the use of different exchange rates are included as foreign currency translation within the condensed consolidated statements of operations and comprehensive loss and condensed consolidated statements of changes in stockholders’ equity.

Business Combinations

The Company uses the provisions of ASC Topic 805, Business Combinations (“ASC 805”) in the accounting for acquisitions of businesses. ASC 805 requires the Company to use the acquisition method of accounting by recognizing the identifiable tangible and intangible assets acquired and liabilities assumed, and any non-controlling interest in the acquired business, measured at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the aforementioned amounts.

While the Company uses its best estimates and assumptions to accurately apply preliminary values to assets acquired and liabilities assumed at the acquisition date, these estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of the assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded in the condensed consolidated statements of operations.

Accounting for business combinations requires management to make significant estimates and assumptions, especially at the acquisition date, including estimates for intangible assets. Although the Company believes the assumptions and estimates that have been made are reasonable and appropriate, they are based in part on historical experience and information obtained from the acquired companies and are inherently uncertain. Estimates in valuing certain of the intangible assets the Company has acquired include future expected cash flows, and discount rates.

Intangible assets

Intangible assets include customer relationships, trade names, and technology, which were primarily acquired as part of the acquisition of XpresSpa in December 2016, HyperPointe in 2022 and Naples Wax Center in 2023 and were recorded based on the estimated fair value in purchase price allocation. In addition, intangible assets include software and website development costs that were capitalized as part of the Company’s development of a mobile application and website for the Treat brand. The Company accounts for these costs in accordance with ASC 350-40, Internal-Use Software. The intangible assets are amortized over their estimated useful lives, which are periodically evaluated for reasonableness.

The Company’s intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The fair value is then compared to the carrying value and an impairment charge is recognized by the amount in which the carrying value exceeds the fair value of the asset. In assessing the recoverability of the Company’s intangible assets, the Company must make estimates and assumptions regarding future cash flows and other factors to determine the fair value of the respective assets. These estimates and assumptions could have a significant impact on whether an impairment charge is recognized and the magnitude of any such charge. Fair value estimates are made at a specific point in time, based on relevant information. During the three and nine months ended September 30, 2024, the Company did not record any intangible impairment loss. During the three and nine months ended September 30, 2023, the Company recorded $2,758 of intangible impairment loss.

Goodwill

Goodwill represents the cost of a business acquisition in excess of the fair value of the net assets acquired. Goodwill is not amortized and is reviewed for impairment annually, or more frequently if facts and circumstances indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. If it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the company performs a quantitative test to identify and measure the amount of goodwill impairment loss. The Company compares the fair value of the reporting unit with its carrying amount. If the carrying amount exceeds fair value, goodwill of the reporting unit is considered impaired,

Table of Contents

and that excess is recognized as a goodwill impairment loss. During the three and nine months ended September 30, 2024, the Company did not record any goodwill impairment loss. During the three and nine months ended September 30, 2023, the Company recorded $4,024 of goodwill impairment loss.

Reclassification

Certain balances in the unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2023, have been reclassified to conform to the presentation in the unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2024, primarily the presentation of revenue, general and administrative expense, the realized and unrealized gain on investments and other operating expenses. The above separation affected revenue classifications, general and administrative expenses, the realized and unrealized gain on investments and other operating expense in the comparative 2023 financial statements. Such reclassifications did not have a material impact on the unaudited condensed consolidated financial statements.

Impairment of Long-Lived Assets

Long-lived assets are tested for impairment at the lowest level at which there are identifiable operating cash flows. The Company’s long-lived assets consist primarily of leasehold improvements and right to use lease assets for each of its locations (considered the asset group). The Company reviews its long-lived assets for recoverability yearly or sooner if events or changes in circumstances indicate that the carrying value of long-lived assets may not be recoverable. If indicators are present, the Company performs a recoverability test by comparing the sum of the estimated undiscounted future cash flows attributable to the asset group in question to its carrying amount. An impairment loss is recognized if it is determined that the long-lived asset group is not recoverable and is calculated based on the excess of the carrying amount of the long-lived asset group over the long-lived asset group’s fair value. The Company estimates the fair value of long-lived assets using present value income approach. Future cash flows are calculated based on forecasts over the estimated remaining useful life of the asset group, which for each of the Company’s locations, is the remaining term of the operating lease.

The estimates used to calculate future cash flows are subjective in nature and involve uncertainties and matters of significant judgments and therefore cannot be determined with precision. Changes in assumptions could significantly affect the estimated fair value of each asset group. The Company will calculate the future cash flow using what it believes to be the most predictable of several scenarios. Typically, the changes in assumptions run under different business scenarios would not result in a material change in the assessment of the potential impairment or the impairment amount of a locations long-lived asset group. But if these estimates or related assumptions were to change materially, the Company may be required to record an impairment charge.

During the three and nine months ended September 30, 2024, the Company recorded impairment of long-lived assets of $0 and $652, respectively compared to $1,096 for the three and nine months ended September 30, 2023, respectively.

Recently Issued Accounting Standards

ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures

In November 2023, the Financial Accounting Standards Board (FASB) issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07), which requires an enhanced disclosure of significant segment expenses on an annual and interim basis. This guidance will be effective for the annual periods beginning the year ended December 31, 2024, and for interim periods beginning January 1, 2025. Early adoption is permitted. Upon adoption, the guidance should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating segment expense disclosures related to its Annual Report on Form 10-K for fiscal year 2024.

Table of Contents

ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual periods beginning the year ended December 31, 2025. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. The Company is currently evaluating income tax disclosures related to its Annual Report on Form 10-K for fiscal year 2025.

Note 3. Potentially Dilutive Securities

The table below presents the computation of basic and diluted net loss per share of Common Stock:


	Three months ended				Nine months ended
	September 30,				September 30,
	2024		2023		2024		2023
Basic numerator:
Net loss attributable to XWELL, Inc.	$	(4,750)	$	(11,531)	$	(9,258)	$	(22,770)
Basic denominator:
Basic weighted average shares outstanding		4,818,681		4,173,894		4,394,106		4,170,629
Basic net (loss) per share	$	(0.99)	$	(2.76)	$	(2.11)	$	(5.46)

Net loss per share data presented above excludes from the calculation of diluted net (loss) income, the following potentially dilutive securities, having an anti-dilutive impact, in case of net loss
Both vested and unvested options to purchase an equal number of shares of Common Stock		439,487		377,717		439,487		377,717
Unvested RSUs to issue an equal number of shares of Common Stock		35,208		14,444		35,208		14,444
Warrants to purchase an equal number of shares of Common Stock		—		200		—		200
Total number of potentially dilutive securities excluded from the calculation of earnings/(loss) per share attributable to common shareholders		474,695		392,361		474,695		392,361

Note 4. Cash, Cash Equivalents, and Restricted Cash

A reconciliation of the Company’s cash and cash equivalents in the Unaudited Condensed Consolidated Balance Sheets to cash, cash equivalents and restricted cash in the Unaudited Condensed Consolidated Statements of Cash Flows as of September 30, 2024, and December 31, 2023 is as follows:


	September 30, 2024		December 31, 2023
Cash denominated in United States dollars	$	1,777	$	5,726
Cash denominated in currency other than United States dollars		2,305		2,395
Restricted cash		751		751
Credit and debit card receivables		283		316
Total cash, cash equivalents and restricted cash	$	5,116	$	9,188

The Company places its cash and temporary cash investments with credit quality institutions. At times, such cash denominated in United States dollars may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insurance

Table of Contents

limit. As of September 30, 2024, and December 31, 2023, deposits in excess of FDIC limits were $2,048 and $4,195, respectively. As of September 30, 2024, and December 31, 2023, the Company held cash balances in overseas accounts, totaling $2,305 and $2,395 respectively, which are not insured by the FDIC. If the Company were to distribute the amounts held overseas, the Company would need to follow an approval and distribution process as defined in its operating and partnership agreements, which may delay and/or reduce the availability of that cash to the Company.

Note 5. Other current assets

As of September 30, 2024, and December 31, 2023, other current assets consisted of the following:


	September 30, 2024		December 31, 2023
Prepaid expenses	$	1,814	$	894
Other		91		55
Total other current assets	$	1,905	$	949

Note 6. Intangible Assets

The following tables provides information regarding the Company’s intangible assets subject to amortization, which consist of the following:


	September 30, 2024						December 31, 2023
	Gross				Net		Gross				Net
	Carrying		Accumulated		Carrying		Carrying		Accumulated		Carrying
	Amount		Amortization		Amount		Amount		Amortization		Amount
Trade names	$	200	$	(23)	$	177	$	200	$	(6)	$	194
Customer relationships		1,012		(416)		596		1,012		(341)		671
Software		2,584		(2,257)		327		2,593		(2,120)		473
Licenses		30		(23)		7		35		(20)		15
Total intangible assets	$	3,826	$	(2,719)	$	1,107	$	3,840	$	(2,487)	$	1,353

The Company’s intangible assets are amortized over their expected useful lives. The Company recorded amortization expense of $78 and $396 during the three months ended September 30, 2024 and 2023, respectively, and $237 and $1,155 during the nine months ended September 30, 2024 and 2023, respectively.

Based on the intangible assets balance as of September 30, 2024, the estimated amortization expense for the remainder of the calendar year and each of the succeeding calendar years is as follows:


Calendar Years ending December 31,	Amount
Remaining 2024	$	79
2025		303
2026		228
2027		122
2028		122
Thereafter		253
Total	$	1,107

Table of Contents

Note 7. Accrued expenses and other current liabilities

As of September 30, 2024, and December 31, 2023, accrued expenses and other current liabilities consisted of the following:



	September 30, 2024		December 31, 2023
Litigation accrual	$	-	$	449
Accrued compensation		1,596		2,098
Tax-related liabilities		488		501
Common area maintenance accruals		439		8
Accounts payable accruals		110		913
Gift certificates		507		509
Credit card processing fees		6		8
Other miscellaneous accruals		546		482
Total accrued expenses and other current liabilities	$	3,692	$	4,968

Note 8. Acquisition of Naples Wax, LLC

On September 12, 2023, the Company acquired all of the equity interests in Naples Wax, LLC, d/b/a Naples Wax Centers, a Florida limited liability company, for an aggregate purchase price of $1,624, of which $1,574 was paid in cash at closing. The remaining $50 was held for six months as a holdback to cover any potential indemnification claims. $14 was paid in the quarter ended March 31, 2024. The remaining $36 was offset by operating expenses.

The Company applies the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 805, Business Combinations (“ASC 805”) in the accounting for acquisitions of businesses. ASC 805 requires the Company to use the acquisition method of accounting by recognizing the identifiable tangible and intangible assets acquired and liabilities assumed, and any non-controlling interest in the acquired business, measured at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the aforementioned amounts.

While the company uses its best estimates and assumptions to accurately apply preliminary values to assets acquired and liabilities assumed at the acquisition date, these estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. As of September 30, 2024, no impairment of the Company’s goodwill was required. The purchase accounting for the acquisition remains incomplete as management continues to gather and evaluate information about circumstances that existed as of the acquisition date. Upon the conclusion of the measurement period or final determination of the values of the assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded in the unaudited condensed consolidated statements of operations.

Accounting for business combinations requires management to make estimates and assumptions, especially at the acquisition date, including estimates for intangible assets. Although the Company believes the assumptions and estimates that have been made are reasonable and appropriate, they are based in part on historical experience and information obtained from the acquired companies and are inherently uncertain. Estimates in valuing certain of the intangible assets the Company has acquired include future expected cash flows, and discount rates.

For income tax purposes, this acquisition of 100% of the units is treated as an asset acquisition. As a result of the acquisition of Naples Wax, the company generated tax deductible goodwill of $1,371.

Note 9. Leases

The Company leases spa and clinic locations at various domestic and international airports. Additionally, the Company leases its corporate office in New York City and other off airport locations in various US cities. Certain leases entered into

Table of Contents

by the Company are accounted for in accordance with ASC 842. The Company determines if an arrangement is a lease at inception and if it qualifies under ASC 842. The Company’s lease arrangements generally contain fixed payments throughout the term of the lease and most also contain a variable component to determine the lease obligation where a certain percentage of sales is used to calculate the lease payments. The Company enters into leases that expire, are amended and extended, or are extended on a month-to-month basis. Leases are not included in the calculation of the total lease liability and the right of use asset when they are month-to-month.

All qualifying leases held by the Company are classified as operating leases. Operating lease assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company records its operating lease assets and liabilities based on required guaranteed payments under each lease agreement. The Company uses its incremental borrowing rate, which approximates the rate at which the Company can borrow funds on a secured basis, using the information available at commencement date of the lease in determining the present value of guaranteed lease payments. The interest rate implicit in the lease is generally not determinable in transactions where a company is the lessee.

The Company reviews all of its existing lease agreements to determine whether there were any modifications to lease agreements and to assess if any agreements should be accounted for pursuant to the guidance in ASC 842.

The following is a summary of the activity in the Company’s current and long-term operating lease liabilities for the nine months ended September 30, 2024 and 2023:


	Nine months ended September 30,
	2024		2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	(2,585)	$	(2,668)
Leased assets obtained in exchange for new and modified operating lease liabilities	$	3,091	$	174

As of September 30, 2024, operating leases contain the following future minimum commitments:


Calendar Years ending December 31,	Amount
Remaining 2024	$	914
2025		2,982
2026		2,184
2027		2,058
2028		1,676
2029		1,421
Thereafter		2,915
Total future lease payments		14,150
Less: interest expense at incremental borrowing rate		(2,534)
Net present value of lease liabilities	$	11,616

Other assumptions and pertinent information related to the Company’s accounting for operating leases are:


Weighted average remaining lease term:	5.75	years
Weighted average discount rate used to determine present value of operating lease liability:	7.10	%

Cash paid for minimum annual rental obligations for the three and nine months ended September 30, 2024, was $433 and $1,202 respectively. Cash paid for minimum annual rental obligations for the three and nine months ended September 30, 2023, was $503 and $1,762 respectively.

Table of Contents

Variable lease payments calculated monthly as a percentage of product and services revenue were $330 and $1,030 for the three and nine months ended September 30, 2024, respectively. Variable lease payments calculated monthly as a percentage of product and services revenue were $302 and $1,013 for the three and nine months ended September 30, 2023, respectively.

Note 10. Other Assets

As of September 30, 2024 and December 31, 2023, assets consisted of the following:


	September 30, 2024		December 31, 2023
Equity investments	$	42	$	50
Lease deposits		1,589		1,556
Other		201		236
Other assets	$	1,832	$	1,842

Note 11. Stockholders’ Equity

August 2024 Registered Direct Offering

On August 6, 2024, the Company entered into a securities purchase agreement with certain institutional and accredited investors, pursuant to which the Company agreed to sell and issue in a registered direct offering (the “August 2024 Offering”), an aggregate of 652,705 shares (the “August 2024 Shares”) of the Company’s common stock. The gross proceeds to the Company from the August 2024 Offering, prior to deducting estimated fees and expenses of $.1 million, were approximately $1.4 million. The August 2024 Offering closed on August 8, 2024.

The August 2024 Shares were offered and sold by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-273726), previously filed with the SEC on August 4, 2023, and declared effective by the SEC on September 29, 2023, and the base prospectus included therein.

Stock-based Compensation

The Company has a stock-based compensation plan available to grant stock options and RSUs to the Company’s directors, employees and consultants.

In September 2020, the Board of Directors approved a new stock-based compensation plan available to grant stock options, restricted stock and Restricted Stock Units (“RSUs”) aggregating to 250,000 shares of Common Stock, to the Company’s directors, employees and consultants. Shareholder approval of the plan was subsequently obtained on October 28, 2020. On October 4, 2022, shareholders approved the amendment to the Company’s 2020 Equity Incentive Plan to increase the number of shares authorized for issuance under the Plan by 375,000 shares of Common Stock to an aggregate of 625,000 shares. Under the 2020 Equity Incentive Plan (the “2020 Plan”), a maximum of 117,775 shares of Common Stock remained available for issuance as of September 30, 2024.

The Company’s previous Employee, Director and Consultant Equity Incentive Plan (the “2012 Plan”) was terminated upon receipt of shareholder approval of the 2020 Plan. Awards granted under the 2012 Plan remain in effect pursuant to their terms. Generally, stock options are granted with exercise prices equal to the fair market value on the date of grant, vest in four equal quarterly installments, and expire 10 years from the date of grant. RSU’s granted generally vest over a period of one year.

In September 2020, XpresTest created a stock-based compensation plan available to grant stock options, restricted stock and RSU’s to the XpresTest’s directors, employees and consultants. Under the XpresTest 2020 Equity Incentive Plan (the “XpresTest Plan”), a maximum of 200 shares of XpresTest common stock may be awarded, which would represent 20% of the total number of shares of common stock of XpresTest as of September 30, 2024. Certain named executive officers, consultants, and directors of the Company are eligible to participate in the XpresTest Plan. The XpresTest Plan RSAs vest

Table of Contents

upon satisfaction of certain service and performance-based conditions. The fair value of the XpresTest Plan RSAs is determined based on the weighted average of (i) Fair Value of XpresTest under the Indirect Valuation Method developing assumptions for XpresSpa Net Market Cap and XpresSpa standalone Fair Value, and (ii) Direct Valuation Method developing assumptions for XpresTest Representative Forecasted Revenue for 2021 and Peer companies Revenue’s Multiples.

As of September 30, 2024, and 2023, there was $27 and $120, respectively of unrecognized stock-based compensation related to the XpresTest Plan.

The fair value of stock options is estimated as of the date of grant using the Black-Scholes-Merton (“Black-Scholes”) option-pricing model. The Company uses the simplified method to estimate the expected term of options due to insufficient history and high turnover in the past.

The following variables were used as inputs in the model:


Share price of the Company’s Common Stock on the grant date:	$	1.50 - 1.80
Exercise price:	$	1.50 - 1.80
Expected volatility:		121.04	%
Expected dividend yield:		0	%
Annual average risk-free rate:		4.05 - 4.14	%
Expected term:		6.32	years

Total stock-based compensation for the three and nine months ended September 30, 2024, was $232 and $818 respectively. Total stock-based compensation for the three and nine months ended September 30, 2023, was $594 and $1,832, respectively. The Company had $368 and $1,319 of unrecognized stock-based compensation related to the XWELL Stock Options, as of September 30, 2024 and December 31, 2023 respectively.

The following tables summarize information about stock options and RSU activity for the nine months ended September 30, 2024:


	RSUs			XpresTest RSAs			Stock options
		Weighted			Weighted			Weighted
		average			average			average		Exercise
	No. of	grant date		No. of	grant date		No. of	exercise		price
	RSUs	fair value		RSAs	fair value		options	price		range
Outstanding as of December 31, 2023	11,944	$	6.08	5	$	47,570	341,205	$	26.85	$	4.60 - 49,200
Granted	30,000		1.80	—		—	180,000	$	1.55	$	1.50 - 1.80
Exercised/Vested	(4,236)		5.67	—		—	(3,000)	$	1.50	$	1.50
Forfeited	(2,500)		5.09	—		—	(29,439)	$	17.47	$	1.50 - 34.40
Expired	—		—	—		—	(49,279)	$	31.18	$	8.00 - 49,200
Outstanding as of September 30, 2024	35,208	$	2.61	5	$	47,570	439,487	$	16.80	$	1.50 - 7,080
Exercisable as of September 30, 2024							375,421	$	15.68	$	1.50 - 7,080

Table of Contents

Note 12. Income Taxes

The Company’s provision for income taxes consists of federal, state, local, and foreign taxes in amounts necessary to align the Company’s year-to-date provision for income taxes with the effective tax rate that the Company expects to achieve for the full year. Each quarter, the Company updates its estimate of the annual effective tax rate and records cumulative adjustments as deemed necessary. The income tax provision for the three and nine months ended September 30, 2024, reflects an estimated global annual effective tax rate of approximately 0% from continuing operations.

As of September 30, 2024, deferred tax assets generated from the Company’s U.S. activities were offset by a valuation allowance because realization depends on generating future taxable income, which, in the Company’s estimation, is not more likely than not to be generated before such net operating loss carryforwards expire. Net operating loss carryforwards generated after December 31, 2017, do not expire. The Company expects its effective tax rate for its current fiscal year to be significantly lower than the statutory rate as a result of a full valuation allowance; therefore, any loss before income taxes does not generate a corresponding income tax benefit. Income tax expense/(benefit) for the three and nine months ended September 30, 2024 was $0, which was attributed to state taxing jurisdictions in which a measure of income is utilized to determine a tax liability. The final annual tax rate cannot be determined until the end of the fiscal year; therefore, the actual tax rate could differ from current estimates.

Note 13. Commitments and Contingencies

Certain of the Company’s outstanding legal matters include speculative claims for substantial or indeterminate amounts of damages. The Company regularly evaluates developments in its legal matters that could affect the amount of any potential liability and adjusts as appropriate. A significant judgment is required to determine both the likelihood of there being any potential liability and the estimated amount of a loss related to the Company’s legal matters.

With respect to the Company’s outstanding legal matters, based on its current knowledge, the Company’s management believes that the amount or range of a potential loss will not, either individually or in the aggregate, have a material adverse effect on its business, consolidated financial position, results of operations or cash flows. However, the outcome of such legal matters is inherently unpredictable and subject to significant uncertainties. The Company evaluated the outstanding legal matters and assessed the probability and likelihood of the occurrence of liability. Based on management’s estimates, the Company has recorded accruals of $0 and $449 as of September 30, 2024 and December 31, 2023, respectively, which is included in Accrued expenses and other current liabilities in the condensed consolidated balance sheets.

The Company expenses legal fees in the period in which they are incurred.

OTG Management PHL B v. XpresSpa Philadelphia Terminal B et al.

On May 9, 2022, a lawsuit was filed in the Philadelphia Court of Common Pleas by OTG Management at Philadelphia International Airport, claiming that XWELL improperly backed out of its sublease for space at Terminal B and now owes between $864 and $2,250 in accelerated rent for the 12-year contract. They claim that by refusing to complete the project, failing to commence and maintain operations, refusing to pay rent and improperly purporting to terminate the lease (among other acts and omissions), XWELL breached the lease. On June 20, 2024, an Order to Settle, Discontinue and End with Prejudice was filed as to all claims.

CPC Pain & Wellness SPV, LLC

On July 19, 2024, CPC Pain & Wellness SPV, LLC (“CPC”), a recently formed special purpose vehicle that announced it had acquired a 9.42% stake in XWELL in June 2024, filed suit in the Court of Chancery of the State of Delaware against the Company, Chairman Bruce T. Bernstein, and directors Michael Lebowitz, Robert Weinstein, Gaëlle Wizenberg, and Scott R. Milford (the “Action”). In the Action, CPC alleged, in pertinent part, that the Board of Directors breached their fiduciary duties and that the Company and Board of Directors engaged in an unlawful, unenforceable, and inequitable application of the Company’s Third Amended and Restated Bylaws to reject CPC’s notice of intent to propose its own slate of directors for election at the 2024 annual meeting of stockholders. On August 2, 2024, the Court set the Action for trial on September 18-19, 2024. The Company has vigorously defended these

Table of Contents

claims. As a result of the Company’s efforts, on August 9, 2024, CPC dismissed all claims in the Action, agreed to irrevocably withdraw its nominations, and agreed not assert any claims related to the 2024 annual meeting.

Settlement Agreement

On August 5, 2024, the Company, XpresSpa Middle East B.V., and certain parties thereto (such parties, the “Settlor Parties” entered into a Settlement Agreement (the “Settlement Agreement”), pursuant to which the Company agreed to issue an aggregate of 416,000 shares of common stock (the “Settlement Shares”) which were issued on August 6, 2024, and have a fair market value of $2.26 per share to the Settlor Parties in consideration for their entry into the Settlement Agreement. The Settlement Shares were not registered under the Securities Act of 1933, as amended (the “Securities Act”), and were issued in reliance on one or more exemptions from registration under the Securities Act, including pursuant to Rule 903 of Regulation S under the Securities Act.

In addition to those matters specifically set forth herein, the Company and its subsidiaries are involved in various other claims and legal actions that arise in the ordinary course of business. The Company does not believe that the ultimate resolution of these actions will have a material adverse effect on the Company’s financial position, results of operations, liquidity, or capital resources. However, a significant increase in the number of these claims, or one or more successful claims under which the Company incurs greater liabilities than the Company currently anticipates, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows.

In the event that an action is brought against the Company or one of its subsidiaries, the Company will investigate the allegation and vigorously defend itself.

Leases

XWELL is contingently liable to a surety company under certain general indemnity agreements required by various airports relating to its lease agreements. XWELL agrees to indemnify the surety for any payments made on contracts of suretyship, guaranty, or indemnity. The Company believes that all contingent liabilities will be satisfied by its performance under the specified lease agreements.

Note 14. Segment Information

As a result of the Company’s transition to a pure-play wellness services company, the Company currently has four reportable operating segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The Company analyzes the results of the Company’s business through the four reportable segments. The XpresSpa segment provides travelers premium spa services, including massage, nail and skin care, as well as spa and travel products. The XpresTest segment provided diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public but has transitioned to the CDC’s bio-surveillance program. XpresTest’s HyperPointe business provides a broad range of service and support options for its customers, including technical support services and advanced services. The Treat segment is a wellness brand that provides access to wellness services for travelers at on-site centers. The Naples Wax Center segment operates three high-performing locations with core products and service offerings from face and body waxing to a range of skincare and cosmetic products. The Treat segment is a wellness brand that provides access to wellness services for travelers at on-site centers.

The chief operating decision maker evaluates the operating results and performance of the Company’s segments through operating income. Expenses that can be specifically identified with a segment have been included as deductions in determining operating income. Any remaining expenses and other charges are included in Corporate and Other.

Table of Contents


	For the three months ended
	September 30,
	2024		2023
Revenue
XpresSpa	$	4,711	$	4,955
XpresTest		3,144		2,322
Naples Wax		429		—
Treat		138		191
Corporate and other		—		—
Total revenue	$	8,422	$	7,468

Operating (loss)	2024		2023
XpresSpa	$	(2,438)	$	(2,947)
XpresTest		1,138		(5,267)
Naples Wax		(66)		—
Treat		81		(1,585)
Corporate and other		(3,484)		(2,290)
Total operating (loss)	$	(4,769)	$	(12,089)

Depreciation & Amortization	2024		2023
XpresSpa	$	187	$	421
XpresTest		16		91
Naples Wax		34		—
Treat		1		66
Corporate and other		14		12
Total Depreciation & Amortization	$	252	$	590

Impairment/loss on disposal of assets	2024		2023
XpresSpa	$	137	$	1,460
XpresTest		—		5,338
Naples Wax		—		—
Treat		15		1,613
Corporate and other		—		—
Total Impairment/loss on disposal of assets	$	152	$	8,411



	For the nine months ended
	September 30,
	2024		2023
Revenue
XpresSpa	$	13,870	$	14,682
XpresTest		10,630		7,541
Naples Wax		1,594		—
Treat		336		483
Total revenue	$	26,430	$	22,706

	2024		2023
Operating loss
XpresSpa	$	(6,620)	$	(8,901)
XpresTest		4,450		(5,067)
Naples Wax		(177)		—
Treat		39		(2,389)
Corporate and other		(6,732)		(6,744)
Total operating loss	$	(9,040)	$	(23,101)

Table of Contents

		For the nine months ended
		September 30,
	2024		2023
Depreciation & amortization
XpresSpa	$	473	$	1,275
XpresTest		72		260
Naples Wax		97		—
Treat		20		198
Corporate and other		43		37
Total depreciation & amortization	$	705	$	1,770

	2024		2023
Impairment/loss on disposal of assets
XpresSpa	$	156	$	1,468
XpresTest		—		5,348
Naples Wax		—		—
Treat		667		1,613
Corporate and other		—		—
Total Impairment/loss on disposal of assets	$	823	$	8,429

	2024		2023
Capital expenditures
XpresSpa	$	861	$	1,596
XpresTest		44		80
Naples Wax		668		—
Treat		4		56
Corporate and other		10		28
Total capital expenditures	$	1,587	$	1,760


	September 30, 2024		December 31, 2023
Long-lived Assets
XpresSpa	$	8,173	$	8,268
XpresTest		26		92
Naples Wax		4,441		1,371
Treat		27		669
Corporate and other		298		438
Total long-lived Assets	$	12,965	$	10,838

	September 30, 2024		December 31, 2023
Assets
XpresSpa	$	18,933	$	18,453
XpresTest		1,395		2,408
Naples Wax		5,573		2,951
Treat		328		848
Corporate and other		7,556		14,333
Total assets	$	33,785	$	38,993

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Quarterly Report on Form 10-Q contains “forward-looking statements” that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The statements contained herein that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipates,” “believes,” “can,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “will be,” “plans,” “projects,” “seeks,” “should,” “targets,” “will,” “would,” and similar expressions or variations intended to identify forward-looking statements. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (the “SEC”) on April 16, 2024, as subsequently amended on April 17, 2024 and April 29, 2024 (the “Annual Report”) and this Quarterly Report on Form 10-Q and any future reports we file with the SEC. The forward-looking statements set forth herein speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

All references in this Quarterly Report on Form 10-Q to “we,” “us” and “our” refer to XWELL, Inc., a Delaware corporation, and its consolidated subsidiaries.

Overview

On October 25, 2022, we changed our name to XWELL, Inc. (“XWELL” or the “Company”) from XpresSpa Group, Inc. Our common stock, par value $0.01 per share, which had previously been listed under the trading symbol “XSPA” on the Nasdaq Capital Market, now trades under the trading symbol “XWEL”. We filed an amended and restated certificate of incorporation with the Delaware Secretary of State on October 24, 2022 (the “Amended and Restated Certificate”) reflecting the name change. Rebranding to XWELL aligned our corporate strategy to build a pure-play wellness services company, in both the airport and off airport marketplaces.

Although we recognize four segments of business, we believe there is opportunity to leverage a segment of our products and services across the Company’s platform of brands. Additionally, we are expanding our retail strategy, not only adding more products for sale but aligning those products more efficiently to our service offerings. This product strategy includes, for example, adding muscle relaxation patches to a neck or back massage to continue treatment after the delivery of the service. We are also continuing to add new service offerings to our in and out of airport locations.

We also plan to build our capability for delivering health and wellness services outside of the airport. We believe operating outside of the airport complements our offering and represents the fastest way to scale the XWELL family of brands.

We will be looking to further expand internationally. With international travel returning to pre-pandemic levels, we continue to be opportunistic in our approach, by taking advantage of the current market to growth. We believe a strategy for international expansion further advances our ability to expand our other brands including bio surveillance outside of the United States.

Table of Contents

XpresSpa

XWELL’s subsidiary, XpresSpa Holdings, LLC (“XpresSpa”) has been a global airport retailer of spa services through our XpresSpa spa locations, offering travelers premium spa services, including massage, nail and skin care, as well as spa and travel products.

As of September 30, 2024, there were 19 domestic XpresSpa locations in total, 17 Company-owned locations and two franchises. We also had 10 international locations operating as of September 30, 2024, including two XpresSpa locations in Dubai International Airport in the United Arab Emirates, one XpresSpa location in Zayad International Airport in Abu Dhabi, UAE, three XpresSpa locations in Schiphol Amsterdam Airport in the Netherlands and four XpresSpa locations in the Istanbul Airport in Turkey.

XpresTest

We, in partnership with certain COVID-19 testing partners, successfully launched its XpresCheck Wellness Centers, in June of 2020, through our XpresTest, Inc. subsidiary (“XpresTest”), which offered COVID-19 and other medical diagnostic testing services to the traveling public, as well as airline, airport and concessionaire employees, and TSA and U.S. Customs and Border Protection agents during the pandemic. During 2022 and 2023, as countries continued to relax their testing requirements resulting in rapid decline of testing volumes at the Company’s XpresCheck Wellness locations, the Company started to close XpresCheck Wellness Centers. As of December 31, 2023, we have closed all XpresCheck Wellness locations.

XpresTest began conducting bio surveillance monitoring with the Centers for Disease Control and Prevention (CDC) in collaboration with Concentric by Ginkgo BioWorks in 2021 and on January 31, 2022, we announced the extension of our initial program, bringing the total contract to $5,537. In August 2022, the program was renewed in partnership with Ginkgo BioWorks. A new two-year contract was initiated which represents approximately $7,330 in revenue (for the first year) for the XpresTest segment.

The program was further renewed in August 2023 through a new one-year contract. The revenue to XpresTest from such one-year extension totaled approximately $7,044. In March 2024, the program funding and scope were expanded, a revenue increase of $4,000, to an estimated $11,044 in revenue for XpresTest with a new collection station located in Miami International Airport (MIA) and the roll out of multi-pathogen testing across the program. The program was further renewed in August 2024.

HyperPointe

XWELL’s subsidiary, gcg Connect, LLC, operating as HyperPointe, provides direct to business marketing support across a number of health and health-related channels. From the creation of marketing campaigns for the pharmaceutical industry, to learning management systems to website and health related content creation, HyperPointe is a complementary service provider to our health-focused brands as well as providing the majority of services to the external community.

For reporting purposes, HyperPointe has been consolidated into the XpresTest segment.

Treat

Treat, which is operating through our subsidiary Treat, Inc. (“Treat”) is a wellness brand that provides access to wellness services for travelers at on-site centers (currently located in JFK International Airport). In April 2024, the decision was made to close the location in the Salt Lake City International Airport.

Treat offers a full retail product offering and a suite of wellness and spa services. Travelers can purchase time blocks to use our wellness rooms to engage in interactive services like self-guided yoga, meditation, and low impact weight exercises or to relax and unplug from the hectic pace of the airport and renew themselves before or after their trip.

Table of Contents

Naples Wax Center

On September 12, 2023, we acquired our subsidiary Naples Wax, LLC d/b/a Naples Wax Centers (“Naples Wax Centers” or “Naples Wax”), a group of upscale hair removal boutiques in Florida, for a purchase price of $1,624. Aiming to provide a memorable customer experience, Naples Wax Center operates three high-performing locations with core products and service offerings from face and body waxing to a range of skincare and cosmetic products. The acquisition of Naples Wax Center is intended to enable us to move beyond our airport client base with a business that can be adapted to a larger wellness platform while also growing our retail footprint to serve our long-term financial goals.

XWELL Studios

In Q4 of 2023, we began plans to open our first XWELL Studios location in Jacksonville, Florida in 2025. XWELL Studios is an out-of-airport concept providing leased space to established wellness service providers. Revenue will be derived from both lease payments received from the wellness practitioners and the sale of retail at the wellness center.

We believe that these strategic imperatives will be accomplished through development of an infrastructure specifically focused on enabling scalable and efficient growth.

Recent Developments

August 2024 Registered Direct Offering

On August 6, 2024, we entered into a securities purchase agreement with certain institutional and accredited investors, pursuant to which we agreed to sell and issue in a registered direct offering (the “August 2024 Offering”), an aggregate of 652,705 shares (the “August 2024 Shares”) of our common stock. The gross proceeds to us from the August 2024 Offering, prior to deducting estimated fees and expenses, were approximately $1.4 million. The August 2024 Offering closed on August 8, 2024.

The August 2024 Shares were offered and sold by us pursuant to a shelf registration statement on Form S-3 (File No. 333-273726), previously filed with the SEC on August 4, 2023, and declared effective by the SEC on September 29, 2023, and the base prospectus included therein.

2023 Reverse Stock Split

On September 28, 2023, we effected a 1-for-20 reverse stock split (the “Reverse Stock Split”), whereby every twenty shares of our common stock were reduced to one share of our common stock and the price per share of our common stock was multiplied by 20. All references to shares and per share amounts, including shares of common stock underlying stock options, warrants, and applicable exercise prices, have been retroactively adjusted for all periods presented herein to give effect to the Reverse Stock Split as required in accordance with US GAAP.

Results of Operations

Revenue

We recognize revenue from the sale of XpresSpa, Treat and Naples Wax services when they are rendered at our stores and from the sale of products at the time goods are purchased at our stores or online (usually by credit card), net of discounts and applicable sales taxes.

During the third quarter of 2022, XpresTest, in partnership with Ginkgo BioWorks in continuation of their support to the CDC’s traveler-based SARS-CoV-2 genomic surveillance program was awarded a new contract. We recognize revenue over time for both sample collection performance obligations, using the input method based on time elapsed to measure progress towards satisfying each of the performance obligations. The Company recognizes revenue ratably (straight line basis) over the term of the contract (one year).

Table of Contents

HyperPointe provides a broad range of service and support options for our customers, including technical support services and advanced services. Technical support services represent the majority of these offerings which are distinct performance obligations that are satisfied over time with revenue recognized ratably over the contract term.

Cost of sales

Cost of sales for our XpresSpa, XpresTest, Naples Wax and Treat segments consist of location and segment level costs. Location and segment level costs include all costs that are directly attributable to operations, primarily payroll and related benefit costs for personnel, occupancy costs and cost of products sold.

General and administrative expenses

General and administrative expenses include management and administrative personnel, overhead and occupancy costs, insurance and various professional fees, as well as stock-based compensation for directors, management and administrative personnel.

Three months ended September 30, 2024, compared to the three months ended September 30, 2023

Revenue


	Three months ended September 30,
	2024		2023		Variance
Total revenue	$	8,422	$	7,468	$	954

The increase in revenue of $954 or 13%, was primarily due to the increase in the XpresTest CDC contract and the addition of Naples Wax.

Cost of sales


	Three months ended September 30,
	2024		2023		Variance
Cost of sales	$	6,369	$	6,377	$	(8)

The decrease in cost of sales of $8, is a result of schedule optimization in the XpresSpa locations. The largest component in the cost of sales is labor costs at the location-level. Cost of sales also includes rent and related occupancy costs, which can primarily include rent based on percentage of sales, as well as other product costs directly associated with the procurement of retail inventory, and other operating costs.

Depreciation and amortization


	Three months ended September 30,
	2024		2023		Variance
Depreciation and amortization	$	252	$	590	$	(338)

The decrease in depreciation and amortization of approximately 57% was primarily due to the write-off of the stores that were permanently closed in 2023. Fewer locations resulted in lower depreciation of leasehold improvements. Depreciation and amortization expense also decreased because of the impairments and disposals of fixed assets during the year ended December 31, 2023 and the three months ended September 30, 2024.

Table of Contents

Impairment/loss on disposal of assets


	Three months ended September 30,
	2024		2023		Variance
Impairment/Loss on disposal of assets	$	152	$	8,411	$	(8,259)

The decrease in loss on disposal of assets of approximately 98% was primarily due to the impairment of intangible and lease right of use assets that occurred in the three months ended September 30, 2023.

General and administrative expenses


	Three months ended September 30,
	2024		2023		Variance
General and administrative	$	4,525	$	3,001	$	1,524

The increase of approximately 51%, or approximately $1.5 million was primarily attributable to the increase in one-time legal fees of approximately $2.1 million related to the defense of the CPC lawsuit in the three months ended September 30, 2024. This was partially offset by a $.6 million reduction in various other administrative expenses.

Salaries and benefits


	Three months ended September 30,
	2024		2023		Variance
Salaries and benefits	$	1,893	$	1,178	$	715

The increase of approximately 61% was primarily due to increased in payroll accruals, including $.4 million in severance related to the executive management change and employee retention credits (ERC) of approximately $1.1 million which reduced prior year salary expenses that were applied in August 2023.

Other non-operating expense, net


	Three months ended September 30,
	2024		2023		Variance
Other non-operating income (expense), net	$	(73)	$	(178)	$	105

The following is a summary of the transactions included in other non-operating expense, net for the three months ended September 30, 2024 and 2023:


	Three months ended September 30,
	2024		2023
Bank fees and financing charges		(50)		(178)
Other		(23)		—
Total	$	(73)	$	(178)

Table of Contents

Interest income, net


	Three months ended September 30,
	2024		2023		Variance
Interest income, net	$	100	$	105	$	(5)

The decrease of $5 was primarily due to having less cash in interest bearing accounts.

Nine months ended September 30, 2024, compared to the nine months ended September 30, 2023

Revenue


	Nine months ended September 30,
	2024		2023		Variance
Total revenue	$	26,430	$	22,706	$	3,724

The increase in revenue of $3,724 or 16%, was primarily due to the increase in the XpresTest CDC contract and the addition of Naples Wax.

Cost of sales


	Nine months ended September 30,
	2024		2023		Variance
Cost of sales	$	18,633	$	19,903	$	(1,270)

The decrease in cost of sales of $1,270 or 6%, is a result of three XpresSpa locations closing during 2023. The largest component in the cost of sales is labor costs at the location-level. Cost of sales also includes rent and related occupancy costs, which can primarily include rent based on percentage of sales, as well as other product costs directly associated with the procurement of retail inventory, and other operating costs.

Depreciation and amortization


	Nine months ended September 30,
	2024		2023		Variance
Depreciation and amortization	$	705	$	1,770	$	(1,065)

The decrease in depreciation and amortization of approximately 60% was primarily due to the write-off of the stores that were permanently closed in 2023. Fewer locations resulted in lower depreciation of leasehold improvements. Depreciation and amortization expense also decreased because of the impairments and disposals of fixed assets during the year ended December 31, 2023 and the nine months ended September 30, 2024.

Table of Contents

Impairment/loss on disposal of assets


	Nine months ended September 30,
	2024		2023		Variance
Impairment/Loss on disposal of assets	$	823	$	8,429	$	(7,606)

The decrease of approximately $7,606 was primarily due to the impairment of tangible, right of use, and intangible assets that occurred in the three months ended September 30, 2023.

General and administrative expenses


	Nine months ended September 30,
	2024		2023		Variance
General and administrative	$	9,682	$	10,282	$	(600)

The decrease of approximately 6% was primarily due to rightsizing our existing business and optimizing our cost structure. We have significantly reduced operating and overhead expenses while we continue to focus on returning to overall profitability. This was partially offset by an increase in one-time legal fees of approximately $2.1 million related to the defense of the CPC lawsuit.

Salaries and benefits


	Nine months ended September 30,
	2024		2023		Variance
Salaries and benefits	$	5,627	$	5,423	$	204

The increase of approximately 4% was primarily due to increased payroll accruals, including $.4 million in severance related to the executive management change and employee retention credits (ERC) of approximately $1.1 million which reduced prior year salary expenses that were applied in August 2023.

Other non-operating expense, net


	Nine months ended September 30,
	2024		2023		Variance
Other non-operating income (expense), net	$	(205)	$	(292)	$	87

The following is a summary of the transactions included in other non-operating expense, net for the nine months ended September 30, 2024 and 2023:


	Nine months ended September 30,
	2024		2023
Bank fees and financing charges		(140)		(282)
Other		(65)		(10)
Total	$	(205)	$	(292)

Table of Contents

Interest income, net


	Nine months ended September 30,
	2024		2023		Variance
Interest income, net	$	308	$	334	$	(26)

The decrease of $26 was primarily due to having less cash in interest bearing accounts.

Liquidity and Capital Resources

As of September 30, 2024, we had cash and cash equivalents of $4,365 (excluding restricted cash), $11,660 in marketable securities, and total current assets of $19,513. Our total current liabilities balance, which includes accounts payable, deferred revenue, accrued expenses, and operating lease liabilities was $9,850 as of September 30, 2024, and $9,330 as of December 31, 2023. The working capital surplus was $9,663 as of September 30, 2024, compared to a working capital surplus of $17,236 as of December 31, 2023.

We have carried out an assessment of our ability to continue as a going concern. As of the date of this Quarterly Report on Form 10-Q, we believe that we have sufficient liquidity to fund operations for the next twelve months. Our primary liquidity and capital requirements are for the maintenance of our current XpresSpa and Treat locations and brand, as well as the expansion of Naples Wax and our off-airport strategy. During the nine months ended September 30, 2024 and 2023, we used $7,541 and $12,873 in operations, respectively.

On August 31, 2021, our board of directors initially authorized a stock repurchase program that permitted the purchase and repurchase of up to 750,000 shares of our common stock through September 15, 2022. In May 2022, the Board increased the share repurchase program by an additional 500,000 shares and extended its effectiveness through September 15, 2023. Under this stock repurchase program, management has discretion in determining the conditions under which shares may be purchased from time to time. The program does not require us to repurchase any specific number of shares, and may be modified, suspended or terminated at any time without prior notice.

Critical Accounting Estimates

The unaudited condensed consolidated financial statements included with this Quarterly Report on Form 10Q should be read in conjunction with the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023, as amended, filed with the SEC which includes a description of our critical accounting estimates that involve subjective and complex judgments that could potentially affect reported results. There have been no material changes to our critical accounting estimates as to the methodologies or assumptions we apply under them. We continue to monitor such methodologies and assumptions.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) or Rule 15d-15(e) promulgated under the Exchange Act) that are designed to ensure that information required to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such

Table of Contents

information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer (Principal Financial and Accounting Officer), as appropriate, to allow timely decisions regarding required disclosure.

As of September 30, 2024, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures.

This type of evaluation is performed on a quarterly basis so that conclusions of management, including our Chief Executive Officer and the Chief Financial Officer, concerning the effectiveness of the disclosure controls can be reported in our periodic reports on Form 10-Q and Form 10-K. The overall goals of these evaluation activities are to monitor our disclosure controls and to modify them as necessary. We intend to maintain the disclosure controls as dynamic systems that we adjust as circumstances merit. Based on the foregoing, our Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of September 30, 2024.

Remediation Plan for Material Weakness in Internal Control over Financial Reporting

Management is committed to the remediation of the Company’s material weaknesses, as well as the continued improvement of the Company’s internal control over financial reporting. Management has implemented, and continues to implement, the actions described below to remediate the underlying causes of the control deficiencies that gave rise to the material weaknesses. Until the remediation efforts described below, including any additional measures management identifies as necessary, are completed, the material weaknesses described above will continue to exist. We cannot provide any assurance that the below remediation efforts will be successful or that our internal control over financial reporting will be effective as a result of these efforts. Management has commenced the following actions and will continue to assess additional opportunities for remediation on an ongoing basis:

The Company has turned on the multi-currency features related to its cloud-based accounting systems.

The Company has engaged outside service providers to assist with the valuation, accounting, and recording of key reporting areas such as leases, revenue recognition and stock compensation expense.

The Company has contracted an independent consulting firm to assist with the preparation of the Financial Statements and U.S. GAAP accounting research.

The Company has engaged outside service providers to review the applicable complementary user entity controls described in the service organizations’ reports for their potential impact on the Company’s financial reporting.

Changes in Internal Control over Financial Reporting

Other than as set forth in the foregoing paragraph, there have been no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the nine months ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

For information regarding legal proceedings, see Note 13. “Commitments and Contingencies” in our notes to the unaudited condensed consolidated financial statements included in “Item 1. Condensed Consolidated Financial Statements (Unaudited).”

Table of Contents

Item 1A. Risk Factors.

There have been no material changes to the risk factors discussed in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2023.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Table of Contents

Item 6. Exhibits.


Exhibit No.		Description


3.1	Certificate of Designation of Series A Junior Participating Preferred Stock, filed with the Secretary of State of the State of Delaware on August 16, 2024 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on August 16, 2024).

4.1	Tax Benefits Preservation Plan, dated as of August 16, 2024, between XWELL, Inc. and Equiniti Trust Company, LLC, as Rights Agent, together with the following exhibits thereto: Exhibit A — Form of Certificate of Designation of Series A Junior Participating Preferred Stock of XWELL, Inc.; Exhibit B — Form of Right Certificate (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on August 16, 2024).

10.1	Form of Securities Purchase Agreement, dated as of August 6, 2024, by and among the Company and the purchasers signatory thereto (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on August 7, 2024).

10.2	Executive Employment Agreement by and between XWELL, Inc. and Ezra T. Ernst, effective as of September 4, 2024 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 5, 2024).
10.3	Transition and Severance Agreement, by and between XWELL, Inc. and Scott R. Milford, effective as of September 4, 2024 (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on September 5, 2024).

31.1*	Certification of Principal Executive Officer pursuant to Exchange Act, Rules 13a – 14(a) and 15d – 14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*		Certification of Principal Financial Officer pursuant to Exchange Act, Rules 13a – 14(a) and 15d – 14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32**		Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS*		Inline XBRL Instance Document

101.SCH*		Inline XBRL Taxonomy Extension Schema Document

101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

*		Filed herewith.

**		Furnished herein.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		XWELL, Inc.


Date:	November 14, 2024	By:	/s/ Ezra T. Ernst
			Ezra T. Ernst
			Chief Executive Officer
			(Principal Executive Officer)


Date:	November 14, 2024	By:	/s/ Suzanne A. Scrabis
			Suzanne A. Scrabis
			Chief Financial Officer
			(Principal Financial and Accounting Officer)

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Ezra T. Ernst, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of XWELL, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s first fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 14, 2024


	/s/ EZRA T. ERNST
	Chief Executive Officer
	(Principal Executive Officer)

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Suzanne A. Scrabis, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of XWELL, Inc.;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 14, 2024


	/s/ SUZANNE A. SCRABIS
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

Exhibit 32

CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of XWELL, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report for the quarter ended September 30, 2024 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: November 14, 2024

	/s/ EZRA T. ERNST
	Ezra T. Ernst
	Chief Executive Officer
	(Principal Executive Officer)


	/s/ SUZANNE A. SCRABIS
	Suzanne A. Scrabis
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2024	Nov. 14, 2024
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-34785
Entity Registrant Name	XWELL, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-4988129
Entity Address, Address Line One	254 West 31st Street
Entity Address, Address Line Two	11th Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10001
City Area Code	212
Local Phone Number	750-9595
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	XWEL
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,256,024
Entity Central Index Key	0001410428
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 4,365	$ 8,437
Marketable securities	11,660	14,613
Accounts receivable	914	1,667
Inventory	669	900
Other current assets	1,905	949
Total current assets	19,513	26,566
Restricted cash	751	751
Property and equipment, net	2,959	2,454
Intangible assets, net	1,107	1,353
Operating lease right of use assets, net	6,234	4,656
Goodwill	1,389	1,371
Other assets	1,832	1,842
Total assets	33,785	38,993
Current liabilities
Accounts payable	2,704	1,099
Accrued expenses and other current liabilities	3,692	4,968
Current portion of operating lease liabilities	2,508	2,402
Deferred revenue	946	861
Total current liabilities	9,850	9,330
Long-term liabilities
Operating lease liabilities	9,108	8,692
Total liabilities	18,958	18,022
Commitments and contingencies (see Note 13)
Equity
Common Stock, $0.01 par value per share, 150,000,000 shares authorized; 5,256,024 and 4,179,631 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively	53	42
Additional paid-in capital	473,773	470,737
Accumulated deficit	(465,111)	(455,853)
Accumulated other comprehensive loss	(2,411)	(1,924)
Total equity attributable to XWELL, Inc.	6,304	13,002
Noncontrolling interests	8,523	7,969
Total equity	14,827	20,971
Total liabilities and equity	$ 33,785	$ 38,993

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
CONDENSED CONSOLIDATED BALANCE SHEETS
Common stock, par value	$ 0.01	$ 0.01
Common stock, authorized	150,000,000	150,000,000
Common stock, issued	5,256,024	4,179,631
Common stock, outstanding	5,256,024	4,179,631

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue, net
Total revenue, net	$ 8,422	$ 7,468	$ 26,430	$ 22,706
Cost of sales
Labor	4,426	4,462	13,235	13,609
Occupancy	919	1,063	2,564	3,237
Products and other operating costs	1,024	852	2,834	3,057
Total cost of sales	6,369	6,377	18,633	19,903
Gross Profit	2,053	1,091	7,797	2,803
Depreciation and amortization	252	590	705	1,770
Impairment of long-lived assets		7,878	652	7,878
Impairment of operating lease right-of-use assets		517		517
Loss on disposal of assets	152	16	171	34
General and administrative	4,525	3,001	9,682	10,282
Salaries and benefits	1,893	1,178	5,627	5,423
Total operating expenses	6,822	13,180	16,837	25,904
Operating loss	(4,769)	(12,089)	(9,040)	(23,101)
Interest income, net	100	105	308	334
Gain on investments, realized and unrealized	106	205	293	650
Foreign exchange gain (loss)	(69)	366	(210)	(690)
Other non-operating expense, net	(73)	(178)	(205)	(292)
Loss before income taxes	(4,705)	(11,591)	(8,854)	(23,099)
Income tax expense
Net loss	(4,705)	(11,591)	(8,854)	(23,099)
Net loss (income) attributable to noncontrolling interests	(45)	60	(404)	329
Net loss attributable to XWELL, Inc.	(4,750)	(11,531)	(9,258)	(22,770)
Net loss	(4,705)	(11,591)	(8,854)	(23,099)
Other comprehensive loss from operations	(247)	(514)	(487)	(1,108)
Comprehensive loss	$ (4,952)	$ (12,105)	$ (9,341)	$ (24,207)
Loss per share
Basic loss per share (in dollars per share)	$ (0.99)	$ (2.76)	$ (2.11)	$ (5.46)
Diluted loss per share (in dollars per share)	$ (0.99)	$ (2.76)	$ (2.11)	$ (5.46)
Weighted-average number of shares outstanding during the period
Basic (in shares)	4,818,681	4,173,894	4,394,106	4,170,629
Diluted (in shares)	4,818,681	4,173,894	4,394,106	4,170,629
Services
Revenue, net
Total revenue, net	$ 7,486	$ 6,721	$ 23,924	$ 20,662
Products
Revenue, net
Total revenue, net	$ 936	$ 747	$ 2,506	$ 2,044

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Common stock	Additional paid-in capital	Accumulated deficit	Accumulated other comprehensive loss	Total Company equity	Non-controlling interests	Total
Balance Beginning at Dec. 31, 2022	$ 42	$ 468,530	$ (428,112)	$ (534)	$ 39,926	$ 8,023	$ 47,949
Common Stock, Shares, Outstanding, Beginning Balance at Dec. 31, 2022	4,161,613
Issuance of restricted stock units (in shares)	6,015
Value of shares Withheld to fund payroll taxes		(22)			(22)		(22)
Stock-based compensation		589			589	23	612
Foreign currency translation				(130)	(130)	11	(119)
Net loss for the period			(5,509)		(5,509)	(320)	(5,829)
Balance Ending at Mar. 31, 2023	$ 42	469,097	(433,621)	(664)	34,854	7,737	42,591
Common Stock, Shares, Outstanding, Ending Balance at Mar. 31, 2023	4,167,628
Balance Beginning at Dec. 31, 2022	$ 42	468,530	(428,112)	(534)	39,926	8,023	47,949
Common Stock, Shares, Outstanding, Beginning Balance at Dec. 31, 2022	4,161,613
Net loss for the period							(23,099)
Balance Ending at Sep. 30, 2023	$ 42	470,270	(450,882)	(1,642)	17,788	7,869	25,657
Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2023	4,174,381
Balance Beginning at Mar. 31, 2023	$ 42	469,097	(433,621)	(664)	34,854	7,737	42,591
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2023	4,167,628
Issuance of restricted stock units (in shares)	3,297
Stock-based compensation		603			603	23	626
Distributions to noncontrolling interests						(120)	(120)
Foreign currency translation				(464)	(464)	46	(418)
Net loss for the period			(5,730)		(5,730)	51	(5,679)
Balance Ending at Jun. 30, 2023	$ 42	469,700	(439,351)	(1,128)	29,263	7,737	37,000
Common Stock, Shares, Outstanding, Ending Balance at Jun. 30, 2023	4,170,925
Issuance of restricted stock units (in shares)	3,456
Stock-based compensation		567			567	24	591
Grant of stock for services		3			3		3
Distributions to noncontrolling interests						150	150
Foreign currency translation				(514)	(514)	18	(496)
Net loss for the period			(11,531)		(11,531)	(60)	(11,591)
Balance Ending at Sep. 30, 2023	$ 42	470,270	(450,882)	(1,642)	17,788	7,869	25,657
Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2023	4,174,381
Balance Beginning at Dec. 31, 2023	$ 42	470,737	(455,853)	(1,924)	13,002	7,969	$ 20,971
Common Stock, Shares, Outstanding, Beginning Balance at Dec. 31, 2023	4,179,631						4,179,631
Issuance of restricted stock units (in shares)	2,986
Stock-based compensation		259			259	23	$ 282
Foreign currency translation				(175)	(175)	45	(130)
Net loss for the period			(2,512)		(2,512)	154	(2,358)
Balance Ending at Mar. 31, 2024	$ 42	470,996	(458,365)	(2,099)	10,574	8,191	18,765
Common Stock, Shares, Outstanding, Ending Balance at Mar. 31, 2024	4,182,617
Balance Beginning at Dec. 31, 2023	$ 42	470,737	(455,853)	(1,924)	13,002	7,969	$ 20,971
Common Stock, Shares, Outstanding, Beginning Balance at Dec. 31, 2023	4,179,631						4,179,631
Net loss for the period							$ (8,854)
Balance Ending at Sep. 30, 2024	$ 53	473,773	(465,111)	(2,411)	6,304	8,523	$ 14,827
Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2024	5,256,024						5,256,024
Balance Beginning at Mar. 31, 2024	$ 42	470,996	(458,365)	(2,099)	10,574	8,191	$ 18,765
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2024	4,182,617
Issuance of restricted stock units (in shares)	818
Exercise of stock options		4			4		4
Exercise of stock options (in shares)	3,000
Stock-based compensation		281			281	23	304
Foreign currency translation				(65)	(65)	11	(54)
Net loss for the period			(1,996)		(1,996)	205	(1,791)
Balance Ending at Jun. 30, 2024	$ 42	471,281	(460,361)	(2,164)	8,798	8,430	17,228
Common Stock, Shares, Outstanding, Ending Balance at Jun. 30, 2024	4,186,435
Issuance of restricted stock units (in shares)	884
Stock issued related to legal settlement	$ 4	936			940		940
Stock issued related to legal settlement (in shares)	416,000
Stock-based compensation		208			208	24	232
Proceeds from registered offering	$ 7	1,348			1,355		1,355
Proceeds from registered offering (in shares)	652,705
Foreign currency translation				(247)	(247)	24	(223)
Net loss for the period			(4,750)		(4,750)	45	(4,705)
Balance Ending at Sep. 30, 2024	$ 53	$ 473,773	$ (465,111)	$ (2,411)	$ 6,304	$ 8,523	$ 14,827
Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2024	5,256,024						5,256,024

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)	Sep. 28, 2023
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
Reverse stock split, conversion ratio	0.05

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities
Net loss	$ (8,854)	$ (23,099)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	705	1,770
Impairment/loss on disposal of fixed assets	569	8,429
Impairment of operating lease right-of-use assets	254
Unrealized gain on marketable securities	(301)	(668)
Gain on Lease Termination	(655)	(821)
Foreign currency remeasurement loss	210	690
Amortization of operating lease right of use asset	928	1,163
Stock-based compensation	818	1,832
(Gain) loss on equity investment	8	53
Changes in assets and liabilities:
Decrease in inventory	231	192
Decrease in accounts receivable	746	1,665
(Increase) in other assets, current and non-current	(1,233)	(336)
Increase (decrease) in deferred revenue	85	(266)
(Decrease) in other liabilities, current and non-current	(2,143)	(3,226)
Increase (decrease) in accounts payable	1,091	(251)
Net cash used in operating activities	(7,541)	(12,873)
Cash flows from investing activities
Acquisition of property and equipment	(1,054)	(1,639)
Investment in marketable securities	(238)	(1,991)
Acquisition of Naples Wax net of cash assumed		(1,574)
Sale of marketable securities	3,492	4,500
Acquisition of intangibles	(9)	(468)
Net cash provided by (used in) investing activities	2,191	(1,172)
Cash flows from financing activities
Contributions from noncontrolling interests		150
Net proceeds from stock sale	1,355
Payments for shares withheld on vesting		(22)
Stock options exercised	4
Distributions to noncontrolling interests		(120)
Net cash provided by financing activities	1,359	8
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(81)	(174)
Decrease in cash, cash equivalents and restricted cash	(4,072)	(14,211)
Cash, cash equivalents, and restricted cash at beginning of the period	9,188	19,789
Cash, cash equivalents, and restricted cash at end of the period	5,116	5,578
Cash paid for
Income taxes	36	142
Non-cash investing and financing transactions
Issuance of shares of Common Stock for legal settlement	940
Capital expenditures included in Accounts payable, accrued expenses and other current liabilities	$ 521	$ 197

Business, Basis of Presentation and Liquidity

9 Months Ended

Sep. 30, 2024

Business, Basis of Presentation and Liquidity

Business, Basis of Presentation and Liquidity

Note 1. Business, Basis of Presentation and Liquidity

Overview

XpresSpa

XpresTest

HyperPointe

For reporting purposes, the former HyperPointe segment has been consolidated into the XpresTest segment.

Treat

Naples Wax Center

XWELL Studios

Basis of Presentation and Principles of Consolidation

Reverse Stock Split

Liquidity and Financial Condition

The Company has significantly reduced operating and overhead expenses, while it continues to focus on returning to overall profitability.

Accounting and Reporting Policies

9 Months Ended

Sep. 30, 2024

Accounting and Reporting Policies

Accounting and Reporting Policies

Note 2. Accounting and Reporting Policies

Use of estimates

Revenue Recognition Policy

XpresSpa, Treat and Naples Wax Center

XpresTest

HyperPointe

Gift cards, customer rewards and prepaid packages

Translation into United States dollars

Business Combinations

Intangible assets

Goodwill

Reclassification

Impairment of Long-Lived Assets

Recently Issued Accounting Standards

ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures

ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures

Potentially Dilutive Securities

9 Months Ended

Sep. 30, 2024

Potentially Dilutive Securities

Potentially Dilutive Securities

Note 3. Potentially Dilutive Securities

The table below presents the computation of basic and diluted net loss per share of Common Stock:


	Three months ended				Nine months ended
	September 30,				September 30,
	2024		2023		2024		2023
Basic numerator:
Net loss attributable to XWELL, Inc.	$	(4,750)	$	(11,531)	$	(9,258)	$	(22,770)
Basic denominator:
Basic weighted average shares outstanding		4,818,681		4,173,894		4,394,106		4,170,629
Basic net (loss) per share	$	(0.99)	$	(2.76)	$	(2.11)	$	(5.46)

Net loss per share data presented above excludes from the calculation of diluted net (loss) income, the following potentially dilutive securities, having an anti-dilutive impact, in case of net loss
Both vested and unvested options to purchase an equal number of shares of Common Stock		439,487		377,717		439,487		377,717
Unvested RSUs to issue an equal number of shares of Common Stock		35,208		14,444		35,208		14,444
Warrants to purchase an equal number of shares of Common Stock		—		200		—		200
Total number of potentially dilutive securities excluded from the calculation of earnings/(loss) per share attributable to common shareholders		474,695		392,361		474,695		392,361

Cash, Cash Equivalents, and Restricted Cash

9 Months Ended

Sep. 30, 2024

Cash, Cash Equivalents, and Restricted Cash

Cash, Cash Equivalents, and Restricted Cash

Note 4. Cash, Cash Equivalents, and Restricted Cash


	September 30, 2024		December 31, 2023
Cash denominated in United States dollars	$	1,777	$	5,726
Cash denominated in currency other than United States dollars		2,305		2,395
Restricted cash		751		751
Credit and debit card receivables		283		316
Total cash, cash equivalents and restricted cash	$	5,116	$	9,188

Other current assets

9 Months Ended

Sep. 30, 2024

Other current assets

Other current assets

Note 5. Other current assets

As of September 30, 2024, and December 31, 2023, other current assets consisted of the following:


	September 30, 2024		December 31, 2023
Prepaid expenses	$	1,814	$	894
Other		91		55
Total other current assets	$	1,905	$	949

Intangible Assets

9 Months Ended

Sep. 30, 2024

Intangible Assets

Intangible Assets

Note 6. Intangible Assets

The following tables provides information regarding the Company’s intangible assets subject to amortization, which consist of the following:


	September 30, 2024						December 31, 2023
	Gross				Net		Gross				Net
	Carrying		Accumulated		Carrying		Carrying		Accumulated		Carrying
	Amount		Amortization		Amount		Amount		Amortization		Amount
Trade names	$	200	$	(23)	$	177	$	200	$	(6)	$	194
Customer relationships		1,012		(416)		596		1,012		(341)		671
Software		2,584		(2,257)		327		2,593		(2,120)		473
Licenses		30		(23)		7		35		(20)		15
Total intangible assets	$	3,826	$	(2,719)	$	1,107	$	3,840	$	(2,487)	$	1,353

Based on the intangible assets balance as of September 30, 2024, the estimated amortization expense for the remainder of the calendar year and each of the succeeding calendar years is as follows:


Calendar Years ending December 31,	Amount
Remaining 2024	$	79
2025		303
2026		228
2027		122
2028		122
Thereafter		253
Total	$	1,107

Accrued expenses and other current liabilities

9 Months Ended

Sep. 30, 2024

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities

Note 7. Accrued expenses and other current liabilities

As of September 30, 2024, and December 31, 2023, accrued expenses and other current liabilities consisted of the following:



	September 30, 2024		December 31, 2023
Litigation accrual	$	-	$	449
Accrued compensation		1,596		2,098
Tax-related liabilities		488		501
Common area maintenance accruals		439		8
Accounts payable accruals		110		913
Gift certificates		507		509
Credit card processing fees		6		8
Other miscellaneous accruals		546		482
Total accrued expenses and other current liabilities	$	3,692	$	4,968

Acquisition of Naples Wax, LLC

9 Months Ended

Sep. 30, 2024

Acquisition of Naples Wax, LLC

Acquisition of Naples Wax, LLC

Note 8. Acquisition of Naples Wax, LLC

Leases

9 Months Ended

Sep. 30, 2024

Leases

Leases

Note 9. Leases

The following is a summary of the activity in the Company’s current and long-term operating lease liabilities for the nine months ended September 30, 2024 and 2023:


	Nine months ended September 30,
	2024		2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	(2,585)	$	(2,668)
Leased assets obtained in exchange for new and modified operating lease liabilities	$	3,091	$	174

As of September 30, 2024, operating leases contain the following future minimum commitments:


Calendar Years ending December 31,	Amount
Remaining 2024	$	914
2025		2,982
2026		2,184
2027		2,058
2028		1,676
2029		1,421
Thereafter		2,915
Total future lease payments		14,150
Less: interest expense at incremental borrowing rate		(2,534)
Net present value of lease liabilities	$	11,616

Other assumptions and pertinent information related to the Company’s accounting for operating leases are:


Weighted average remaining lease term:	5.75	years
Weighted average discount rate used to determine present value of operating lease liability:	7.10	%

Other Assets

9 Months Ended

Sep. 30, 2024

Other Assets

Other Assets

Note 10. Other Assets

As of September 30, 2024 and December 31, 2023, assets consisted of the following:


	September 30, 2024		December 31, 2023
Equity investments	$	42	$	50
Lease deposits		1,589		1,556
Other		201		236
Other assets	$	1,832	$	1,842

Stockholders' Equity

9 Months Ended

Sep. 30, 2024

Stockholders' Equity

Stockholders' Equity

Note 11. Stockholders’ Equity

August 2024 Registered Direct Offering

Stock-based Compensation

The Company has a stock-based compensation plan available to grant stock options and RSUs to the Company’s directors, employees and consultants.

As of September 30, 2024, and 2023, there was $27 and $120, respectively of unrecognized stock-based compensation related to the XpresTest Plan.

The following variables were used as inputs in the model:


Share price of the Company’s Common Stock on the grant date:	$	1.50 - 1.80
Exercise price:	$	1.50 - 1.80
Expected volatility:		121.04	%
Expected dividend yield:		0	%
Annual average risk-free rate:		4.05 - 4.14	%
Expected term:		6.32	years

The following tables summarize information about stock options and RSU activity for the nine months ended September 30, 2024:


	RSUs			XpresTest RSAs			Stock options
		Weighted			Weighted			Weighted
		average			average			average		Exercise
	No. of	grant date		No. of	grant date		No. of	exercise		price
	RSUs	fair value		RSAs	fair value		options	price		range
Outstanding as of December 31, 2023	11,944	$	6.08	5	$	47,570	341,205	$	26.85	$	4.60 - 49,200
Granted	30,000		1.80	—		—	180,000	$	1.55	$	1.50 - 1.80
Exercised/Vested	(4,236)		5.67	—		—	(3,000)	$	1.50	$	1.50
Forfeited	(2,500)		5.09	—		—	(29,439)	$	17.47	$	1.50 - 34.40
Expired	—		—	—		—	(49,279)	$	31.18	$	8.00 - 49,200
Outstanding as of September 30, 2024	35,208	$	2.61	5	$	47,570	439,487	$	16.80	$	1.50 - 7,080
Exercisable as of September 30, 2024							375,421	$	15.68	$	1.50 - 7,080

Income Taxes

9 Months Ended

Sep. 30, 2024

Income Taxes

Income Taxes

Note 12. Income Taxes

Commitments and Contingencies

9 Months Ended

Sep. 30, 2024

Commitments and Contingencies

Commitments and Contingencies

Note 13. Commitments and Contingencies

The Company expenses legal fees in the period in which they are incurred.

OTG Management PHL B v. XpresSpa Philadelphia Terminal B et al.

CPC Pain & Wellness SPV, LLC

Settlement Agreement

In the event that an action is brought against the Company or one of its subsidiaries, the Company will investigate the allegation and vigorously defend itself.

Leases

Segment Information

9 Months Ended

Sep. 30, 2024

Segment Information

Segment Information

Note 14. Segment Information


	For the three months ended
	September 30,
	2024		2023
Revenue
XpresSpa	$	4,711	$	4,955
XpresTest		3,144		2,322
Naples Wax		429		—
Treat		138		191
Corporate and other		—		—
Total revenue	$	8,422	$	7,468

Operating (loss)	2024		2023
XpresSpa	$	(2,438)	$	(2,947)
XpresTest		1,138		(5,267)
Naples Wax		(66)		—
Treat		81		(1,585)
Corporate and other		(3,484)		(2,290)
Total operating (loss)	$	(4,769)	$	(12,089)

Depreciation & Amortization	2024		2023
XpresSpa	$	187	$	421
XpresTest		16		91
Naples Wax		34		—
Treat		1		66
Corporate and other		14		12
Total Depreciation & Amortization	$	252	$	590

Impairment/loss on disposal of assets	2024		2023
XpresSpa	$	137	$	1,460
XpresTest		—		5,338
Naples Wax		—		—
Treat		15		1,613
Corporate and other		—		—
Total Impairment/loss on disposal of assets	$	152	$	8,411



	For the nine months ended
	September 30,
	2024		2023
Revenue
XpresSpa	$	13,870	$	14,682
XpresTest		10,630		7,541
Naples Wax		1,594		—
Treat		336		483
Total revenue	$	26,430	$	22,706

	2024		2023
Operating loss
XpresSpa	$	(6,620)	$	(8,901)
XpresTest		4,450		(5,067)
Naples Wax		(177)		—
Treat		39		(2,389)
Corporate and other		(6,732)		(6,744)
Total operating loss	$	(9,040)	$	(23,101)

		For the nine months ended
		September 30,
	2024		2023
Depreciation & amortization
XpresSpa	$	473	$	1,275
XpresTest		72		260
Naples Wax		97		—
Treat		20		198
Corporate and other		43		37
Total depreciation & amortization	$	705	$	1,770

	2024		2023
Impairment/loss on disposal of assets
XpresSpa	$	156	$	1,468
XpresTest		—		5,348
Naples Wax		—		—
Treat		667		1,613
Corporate and other		—		—
Total Impairment/loss on disposal of assets	$	823	$	8,429

	2024		2023
Capital expenditures
XpresSpa	$	861	$	1,596
XpresTest		44		80
Naples Wax		668		—
Treat		4		56
Corporate and other		10		28
Total capital expenditures	$	1,587	$	1,760


	September 30, 2024		December 31, 2023
Long-lived Assets
XpresSpa	$	8,173	$	8,268
XpresTest		26		92
Naples Wax		4,441		1,371
Treat		27		669
Corporate and other		298		438
Total long-lived Assets	$	12,965	$	10,838

	September 30, 2024		December 31, 2023
Assets
XpresSpa	$	18,933	$	18,453
XpresTest		1,395		2,408
Naples Wax		5,573		2,951
Treat		328		848
Corporate and other		7,556		14,333
Total assets	$	33,785	$	38,993

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (4,750)	$ (11,531)	$ (9,258)	$ (22,770)

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Accounting and Reporting Policies (Policies)	9 Months Ended
Accounting and Reporting Policies (Policies)	Sep. 30, 2024
Accounting and Reporting Policies
Use of estimates	Use of estimates The preparation of the accompanying unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses for the periods presented. Actual results may differ from such estimates. Significant items subject to such estimates and assumptions include the Company’s long-lived assets, intangibles assets, the useful lives of the Company’s intangible assets, the valuation of stock-based compensation, deferred tax assets and liabilities, income tax uncertainties, and other contingencies.
Revenue Recognition Policy	Revenue Recognition Policy XpresSpa, Treat and Naples Wax Center The Company recognizes revenue from the sale of products and services when the services are rendered at XpresSpa, Treat, and Naples Wax Centers locations and from the sale of products at the time products are purchased at the Company’s stores or online usually by credit card, net of discounts and applicable sales taxes. Accordingly, the Company recognizes revenue for the Company’s single performance obligation related to both in-store and online sales at the point at which the service has been performed or the control of the merchandise has passed to the customer. The Company recognizes revenue from Priority Pass services when an invoice is generated to Priority Pass detailing the number of services performed multiplied by the agreed upon price. XpresTest During the third quarter of 2022, XpresTest, in partnership with Ginkgo BioWorks in continuation of their support to the CDC’s traveler-based SARS-CoV-2 genomic surveillance program was awarded a new contract. The partnership is expected to support public health and biosecurity services totaling approximately $16,000, with an overall potential to exceed $61,000 based on CDC program options and public health priorities. As COVID-19 sub-variants and other biological threats continue to emerge, the partners plan to expand the program footprint and incorporate innovative modalities and offerings, such as monitoring of wastewater from aircraft lavatories. The current contract with Ginkgo BioWorks related to the above partnership contains fixed pricing for which the Company is entitled to $14,730 for the sample collection (passenger and aircraft wastewater) and $370 for the traveler enrollment initiatives, which represents the amount of consideration that we are entitled. The Company recognizes revenue over time for both sample collection performance obligations, using the input method based on time elapsed to measure progress towards satisfying each of the performance obligations. We recognized the revenue for the traveler enrollment initiative performance obligation in the second quarter of 2023. The Company recognizes revenue ratably (straight line basis) over the term of the contract (one year). The Company recorded $2,542 and $9,289 in revenue for the three and nine months ended September 30, 2024, respectively, and $1,603 and $5,531 in revenue for the three and nine months ended September 30, 2023, respectively related to sample collection performance obligations because the Company’s efforts towards satisfying each of the performance obligations are expended evenly throughout the period of performance. HyperPointe The Company’s HyperPointe business provides a broad range of service and support options for HyperPointe’s customers, including technical support services and advanced services. Technical support services represent the majority of these offerings which are distinct performance obligations that are satisfied over time with revenue recognized ratably over the contract term. Advanced services are distinct performance obligations that are satisfied over time with revenue recognized as services are delivered. Revenues billed in advance are treated as deferred revenue, which was $112 and $72 as of September 30, 2024, and December 31, 2023, respectively. Deferred revenue recognized in the three and nine months ended September 30, 2024, were $0 and $72, respectively. Deferred revenue recognized in the three and nine months ended September 30, 2023, were $111 and $321, respectively. The Company excludes all sales taxes assessed to our customers from revenue. Sales taxes assessed on revenues are included in Accrued expenses and other current liabilities on the Company’s condensed consolidated balance sheets until remitted to state agencies.
Gift cards, customer rewards and prepaid packages	Gift cards, customer rewards and prepaid packages XWELL offers no-fee, non-expiring gift cards to its customers. No revenue is recognized upon the issuance of a gift card and a liability is established for the gift card’s cash value. The liability is relieved, and revenue is recognized upon redemption by the customer. As the gift cards have no expiration date, there is no provision for the reduction in the value of unused card balances. In addition, XWELL maintains a rewards program in which customers earn loyalty points, which can be redeemed for future services. Loyalty points are rewarded upon joining the loyalty program, for customer birthdays, and based upon customer spending. When a customer redeems loyalty points, the Company recognizes revenue for the redeemed cash value and reduces the related loyalty program liability. In 2023, the Company adopted a formal expiration policy whereby any loyalty members with inactivity for an 18-month period will forfeit any unused loyalty rewards. The costs associated with gift cards and reward points are accrued as the rewards are earned by the cardholder and are included in Accrued expenses and other current liabilities in the condensed consolidated balance sheets until used. Naples Wax Center offers prepaid wax packages that are either unlimited for one year or a set number of services. When the packages are purchased, the sales are recorded as deferred revenue. As services related to prepaid packages are used, revenue is recognized as income. The deferred revenue as of September 30, 2024, was $828 and for the year ended December 31, 2023, deferred revenue was $778.
Translation into United States dollars	Translation into United States dollars The Company conducts certain transactions in foreign currencies, which are recorded at the exchange rate as of the transaction date. All exchange gains and losses occurring from the remeasurement of monetary balance sheet items denominated in non-dollar currencies are deemed non-operating income in the condensed consolidated statements of operations and comprehensive loss. During the three and nine months ended September 30, 2024, the Company recorded $69 and $210, respectively, in exchange gains occurring from the remeasurement of monetary balance sheet items denominated in non-dollar currencies. During the three and nine months ended September 30, 2023, the Company recorded $366 in exchange losses and $690 in exchange gains respectively, occurring from the remeasurement of monetary balance sheet items denominated in non-dollar currencies. Accounts of the foreign subsidiaries of XpresSpa are translated into United States dollars. Assets and liabilities have been translated primarily at period end exchange rates and revenues and expenses have been translated at average monthly rates for the three and nine months ended September 30, 2024. The translation adjustments arising from the use of different exchange rates are included as foreign currency translation within the condensed consolidated statements of operations and comprehensive loss and condensed consolidated statements of changes in stockholders’ equity.
Business Combinations	Business Combinations The Company uses the provisions of ASC Topic 805, Business Combinations (“ASC 805”) in the accounting for acquisitions of businesses. ASC 805 requires the Company to use the acquisition method of accounting by recognizing the identifiable tangible and intangible assets acquired and liabilities assumed, and any non-controlling interest in the acquired business, measured at their acquisition date fair values. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the aforementioned amounts. While the Company uses its best estimates and assumptions to accurately apply preliminary values to assets acquired and liabilities assumed at the acquisition date, these estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of the assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded in the condensed consolidated statements of operations. Accounting for business combinations requires management to make significant estimates and assumptions, especially at the acquisition date, including estimates for intangible assets. Although the Company believes the assumptions and estimates that have been made are reasonable and appropriate, they are based in part on historical experience and information obtained from the acquired companies and are inherently uncertain. Estimates in valuing certain of the intangible assets the Company has acquired include future expected cash flows, and discount rates.
Intangible assets	Intangible assets Intangible assets include customer relationships, trade names, and technology, which were primarily acquired as part of the acquisition of XpresSpa in December 2016, HyperPointe in 2022 and Naples Wax Center in 2023 and were recorded based on the estimated fair value in purchase price allocation. In addition, intangible assets include software and website development costs that were capitalized as part of the Company’s development of a mobile application and website for the Treat brand. The Company accounts for these costs in accordance with ASC 350-40, Internal-Use Software. The intangible assets are amortized over their estimated useful lives, which are periodically evaluated for reasonableness. The Company’s intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The fair value is then compared to the carrying value and an impairment charge is recognized by the amount in which the carrying value exceeds the fair value of the asset. In assessing the recoverability of the Company’s intangible assets, the Company must make estimates and assumptions regarding future cash flows and other factors to determine the fair value of the respective assets. These estimates and assumptions could have a significant impact on whether an impairment charge is recognized and the magnitude of any such charge. Fair value estimates are made at a specific point in time, based on relevant information. During the three and nine months ended September 30, 2024, the Company did not record any intangible impairment loss. During the three and nine months ended September 30, 2023, the Company recorded $2,758 of intangible impairment loss.
Goodwill	Goodwill Goodwill represents the cost of a business acquisition in excess of the fair value of the net assets acquired. Goodwill is not amortized and is reviewed for impairment annually, or more frequently if facts and circumstances indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. If it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the company performs a quantitative test to identify and measure the amount of goodwill impairment loss. The Company compares the fair value of the reporting unit with its carrying amount. If the carrying amount exceeds fair value, goodwill of the reporting unit is considered impaired, and that excess is recognized as a goodwill impairment loss. During the three and nine months ended September 30, 2024, the Company did not record any goodwill impairment loss. During the three and nine months ended September 30, 2023, the Company recorded $4,024 of goodwill impairment loss.
Reclassification	Reclassification Certain balances in the unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2023, have been reclassified to conform to the presentation in the unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2024, primarily the presentation of revenue, general and administrative expense, the realized and unrealized gain on investments and other operating expenses. The above separation affected revenue classifications, general and administrative expenses, the realized and unrealized gain on investments and other operating expense in the comparative 2023 financial statements. Such reclassifications did not have a material impact on the unaudited condensed consolidated financial statements.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets are tested for impairment at the lowest level at which there are identifiable operating cash flows. The Company’s long-lived assets consist primarily of leasehold improvements and right to use lease assets for each of its locations (considered the asset group). The Company reviews its long-lived assets for recoverability yearly or sooner if events or changes in circumstances indicate that the carrying value of long-lived assets may not be recoverable. If indicators are present, the Company performs a recoverability test by comparing the sum of the estimated undiscounted future cash flows attributable to the asset group in question to its carrying amount. An impairment loss is recognized if it is determined that the long-lived asset group is not recoverable and is calculated based on the excess of the carrying amount of the long-lived asset group over the long-lived asset group’s fair value. The Company estimates the fair value of long-lived assets using present value income approach. Future cash flows are calculated based on forecasts over the estimated remaining useful life of the asset group, which for each of the Company’s locations, is the remaining term of the operating lease. The estimates used to calculate future cash flows are subjective in nature and involve uncertainties and matters of significant judgments and therefore cannot be determined with precision. Changes in assumptions could significantly affect the estimated fair value of each asset group. The Company will calculate the future cash flow using what it believes to be the most predictable of several scenarios. Typically, the changes in assumptions run under different business scenarios would not result in a material change in the assessment of the potential impairment or the impairment amount of a locations long-lived asset group. But if these estimates or related assumptions were to change materially, the Company may be required to record an impairment charge. During the three and nine months ended September 30, 2024, the Company recorded impairment of long-lived assets of $0 and $652, respectively compared to $1,096 for the three and nine months ended September 30, 2023, respectively.
Recently Issued Accounting Standards	Recently Issued Accounting Standards ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In November 2023, the Financial Accounting Standards Board (FASB) issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07), which requires an enhanced disclosure of significant segment expenses on an annual and interim basis. This guidance will be effective for the annual periods beginning the year ended December 31, 2024, and for interim periods beginning January 1, 2025. Early adoption is permitted. Upon adoption, the guidance should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating segment expense disclosures related to its Annual Report on Form 10-K for fiscal year 2024. ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. This guidance will be effective for the annual periods beginning the year ended December 31, 2025. Early adoption is permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. The Company is currently evaluating income tax disclosures related to its Annual Report on Form 10-K for fiscal year 2025.

Potentially Dilutive Securities (Tables)

9 Months Ended

Sep. 30, 2024

Potentially Dilutive Securities

Schedule of computation of basic and diluted net loss per share of Common Stock


	Three months ended				Nine months ended
	September 30,				September 30,
	2024		2023		2024		2023
Basic numerator:
Net loss attributable to XWELL, Inc.	$	(4,750)	$	(11,531)	$	(9,258)	$	(22,770)
Basic denominator:
Basic weighted average shares outstanding		4,818,681		4,173,894		4,394,106		4,170,629
Basic net (loss) per share	$	(0.99)	$	(2.76)	$	(2.11)	$	(5.46)

Net loss per share data presented above excludes from the calculation of diluted net (loss) income, the following potentially dilutive securities, having an anti-dilutive impact, in case of net loss
Both vested and unvested options to purchase an equal number of shares of Common Stock		439,487		377,717		439,487		377,717
Unvested RSUs to issue an equal number of shares of Common Stock		35,208		14,444		35,208		14,444
Warrants to purchase an equal number of shares of Common Stock		—		200		—		200
Total number of potentially dilutive securities excluded from the calculation of earnings/(loss) per share attributable to common shareholders		474,695		392,361		474,695		392,361

Cash, Cash Equivalents, and Restricted Cash (Tables)

9 Months Ended

Sep. 30, 2024

Cash, Cash Equivalents, and Restricted Cash

Schedule of cash, cash equivalents, and restricted cash


	September 30, 2024		December 31, 2023
Cash denominated in United States dollars	$	1,777	$	5,726
Cash denominated in currency other than United States dollars		2,305		2,395
Restricted cash		751		751
Credit and debit card receivables		283		316
Total cash, cash equivalents and restricted cash	$	5,116	$	9,188

Other current assets (Tables)

9 Months Ended

Sep. 30, 2024

Other current assets

Schedule of other current assets


	September 30, 2024		December 31, 2023
Prepaid expenses	$	1,814	$	894
Other		91		55
Total other current assets	$	1,905	$	949

Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2024

Intangible Assets

Schedule of carrying amounts for intangible assets subject to amortization


	September 30, 2024						December 31, 2023
	Gross				Net		Gross				Net
	Carrying		Accumulated		Carrying		Carrying		Accumulated		Carrying
	Amount		Amortization		Amount		Amount		Amortization		Amount
Trade names	$	200	$	(23)	$	177	$	200	$	(6)	$	194
Customer relationships		1,012		(416)		596		1,012		(341)		671
Software		2,584		(2,257)		327		2,593		(2,120)		473
Licenses		30		(23)		7		35		(20)		15
Total intangible assets	$	3,826	$	(2,719)	$	1,107	$	3,840	$	(2,487)	$	1,353

Schedule of future estimated amortization expense for intangible assets subject to amortization


Calendar Years ending December 31,	Amount
Remaining 2024	$	79
2025		303
2026		228
2027		122
2028		122
Thereafter		253
Total	$	1,107

Accrued expenses and other current liabilities (Tables)

9 Months Ended

Sep. 30, 2024

Accrued expenses and other current liabilities

Schedule of accrued expenses and other current liabilities



	September 30, 2024		December 31, 2023
Litigation accrual	$	-	$	449
Accrued compensation		1,596		2,098
Tax-related liabilities		488		501
Common area maintenance accruals		439		8
Accounts payable accruals		110		913
Gift certificates		507		509
Credit card processing fees		6		8
Other miscellaneous accruals		546		482
Total accrued expenses and other current liabilities	$	3,692	$	4,968

Leases (Tables)

9 Months Ended

Sep. 30, 2024

Leases

Schedule of supplemental cash flow information related to leases


	Nine months ended September 30,
	2024		2023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	(2,585)	$	(2,668)
Leased assets obtained in exchange for new and modified operating lease liabilities	$	3,091	$	174

Schedule of future minimum commitments


Calendar Years ending December 31,	Amount
Remaining 2024	$	914
2025		2,982
2026		2,184
2027		2,058
2028		1,676
2029		1,421
Thereafter		2,915
Total future lease payments		14,150
Less: interest expense at incremental borrowing rate		(2,534)
Net present value of lease liabilities	$	11,616

Schedule of other assumptions and pertinent information


Weighted average remaining lease term:	5.75	years
Weighted average discount rate used to determine present value of operating lease liability:	7.10	%

Other Assets (Tables)

9 Months Ended

Sep. 30, 2024

Other Assets

Schedule of other assets


	September 30, 2024		December 31, 2023
Equity investments	$	42	$	50
Lease deposits		1,589		1,556
Other		201		236
Other assets	$	1,832	$	1,842

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2024

Stockholders' Equity

Schedule of variables used as inputs in calculation of fair value of stock options


Share price of the Company’s Common Stock on the grant date:	$	1.50 - 1.80
Exercise price:	$	1.50 - 1.80
Expected volatility:		121.04	%
Expected dividend yield:		0	%
Annual average risk-free rate:		4.05 - 4.14	%
Expected term:		6.32	years

Schedule of stock options and restricted stock units activity


	RSUs			XpresTest RSAs			Stock options
		Weighted			Weighted			Weighted
		average			average			average		Exercise
	No. of	grant date		No. of	grant date		No. of	exercise		price
	RSUs	fair value		RSAs	fair value		options	price		range
Outstanding as of December 31, 2023	11,944	$	6.08	5	$	47,570	341,205	$	26.85	$	4.60 - 49,200
Granted	30,000		1.80	—		—	180,000	$	1.55	$	1.50 - 1.80
Exercised/Vested	(4,236)		5.67	—		—	(3,000)	$	1.50	$	1.50
Forfeited	(2,500)		5.09	—		—	(29,439)	$	17.47	$	1.50 - 34.40
Expired	—		—	—		—	(49,279)	$	31.18	$	8.00 - 49,200
Outstanding as of September 30, 2024	35,208	$	2.61	5	$	47,570	439,487	$	16.80	$	1.50 - 7,080
Exercisable as of September 30, 2024							375,421	$	15.68	$	1.50 - 7,080

Segment Information (Tables)

9 Months Ended

Sep. 30, 2024

Segment Information

Schedule of segment reporting information, by segment


	For the three months ended
	September 30,
	2024		2023
Revenue
XpresSpa	$	4,711	$	4,955
XpresTest		3,144		2,322
Naples Wax		429		—
Treat		138		191
Corporate and other		—		—
Total revenue	$	8,422	$	7,468

Operating (loss)	2024		2023
XpresSpa	$	(2,438)	$	(2,947)
XpresTest		1,138		(5,267)
Naples Wax		(66)		—
Treat		81		(1,585)
Corporate and other		(3,484)		(2,290)
Total operating (loss)	$	(4,769)	$	(12,089)

Depreciation & Amortization	2024		2023
XpresSpa	$	187	$	421
XpresTest		16		91
Naples Wax		34		—
Treat		1		66
Corporate and other		14		12
Total Depreciation & Amortization	$	252	$	590

Impairment/loss on disposal of assets	2024		2023
XpresSpa	$	137	$	1,460
XpresTest		—		5,338
Naples Wax		—		—
Treat		15		1,613
Corporate and other		—		—
Total Impairment/loss on disposal of assets	$	152	$	8,411



	For the nine months ended
	September 30,
	2024		2023
Revenue
XpresSpa	$	13,870	$	14,682
XpresTest		10,630		7,541
Naples Wax		1,594		—
Treat		336		483
Total revenue	$	26,430	$	22,706

	2024		2023
Operating loss
XpresSpa	$	(6,620)	$	(8,901)
XpresTest		4,450		(5,067)
Naples Wax		(177)		—
Treat		39		(2,389)
Corporate and other		(6,732)		(6,744)
Total operating loss	$	(9,040)	$	(23,101)

		For the nine months ended
		September 30,
	2024		2023
Depreciation & amortization
XpresSpa	$	473	$	1,275
XpresTest		72		260
Naples Wax		97		—
Treat		20		198
Corporate and other		43		37
Total depreciation & amortization	$	705	$	1,770

	2024		2023
Impairment/loss on disposal of assets
XpresSpa	$	156	$	1,468
XpresTest		—		5,348
Naples Wax		—		—
Treat		667		1,613
Corporate and other		—		—
Total Impairment/loss on disposal of assets	$	823	$	8,429

	2024		2023
Capital expenditures
XpresSpa	$	861	$	1,596
XpresTest		44		80
Naples Wax		668		—
Treat		4		56
Corporate and other		10		28
Total capital expenditures	$	1,587	$	1,760


	September 30, 2024		December 31, 2023
Long-lived Assets
XpresSpa	$	8,173	$	8,268
XpresTest		26		92
Naples Wax		4,441		1,371
Treat		27		669
Corporate and other		298		438
Total long-lived Assets	$	12,965	$	10,838

	September 30, 2024		December 31, 2023
Assets
XpresSpa	$	18,933	$	18,453
XpresTest		1,395		2,408
Naples Wax		5,573		2,951
Treat		328		848
Corporate and other		7,556		14,333
Total assets	$	33,785	$	38,993

Business, Basis of Presentation and Liquidity (Details) $ / shares in Units, $ in Thousands			9 Months Ended
	Sep. 28, 2023	Sep. 12, 2023 USD ($) location	Sep. 30, 2024 USD ($) location segment $ / shares	Dec. 31, 2023 USD ($) $ / shares	Oct. 25, 2022 $ / shares
Common stock, par value \| $ / shares			$ 0.01	$ 0.01	$ 0.01
Number of operating segments \| segment			4
Reverse stock split, conversion ratio	0.05
Reverse stock split, multiplying factor for price per share	20
Cash and cash equivalents \| $			$ 4,365	$ 8,437
Marketable securities \| $			11,660	14,613
Total current assets \| $			19,513	26,566
Total current liabilities \| $			9,850	9,330
Working capital \| $			$ 9,663	$ 17,236
XpresSpa \| United States
Number of operating locations			19
Number of operating locations, company-owned			17
Number of operating locations, franchises			2
XpresSpa \| Non-US
Number of operating locations			10
Naples Wax LLC
Consideration paid \| $		$ 1,624
Number of operating locations		3
Dubai International Airport \| XpresSpa \| Non-US
Number of operating locations			2
Zayad International Airport \| XpresSpa \| Non-US
Number of operating locations			1
Schiphol Amsterdam Airport \| XpresSpa \| Non-US
Number of operating locations			3
Istanbul Airport \| XpresSpa \| Non-US
Number of operating locations			4

Accounting and Reporting Policies (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Foreign currency remeasurement gain/(loss)	$ (69)	$ 366		$ (210)	$ (690)
Impairment of intangible assets	0	2,758		0	2,758
Impairment of operating lease right-of-use assets		517			517
Deferred revenue	946			946		$ 861
Impairment loss on goodwill	0	4,024		0	4,024
Impairment of long-lived assets		7,878		652	7,878
Land Improvements
Impairment of long-lived assets	0	1,096		652	1,096
Foreign Currency Gain (Loss)
Foreign currency remeasurement gain/(loss)	69	(366)		$ 210	690
Naples Wax LLC
Deferred revenue, period earned				1 year
Deferred revenue, inactivity period				18 months
Deferred revenue	828			$ 828		778
Impairment loss on goodwill				$ 0
XpresTest
Revenue Contract, Term				1 year
XpresTest \| CDC Program Options and Public Health Services
Unrecognized revenue contract amount			$ 16,000
XpresTest \| Traveler Enrollment Initiatives \| CDC Program Options and Public Health Services
Revenue recognized			370
XpresTest \| Passenger and Aircraft Wastewater Sample Collection \| CDC Program Options and Public Health Services
Revenue recognized	2,542	1,603		$ 9,289	5,531
Unrecognized revenue contract amount			14,730
HyperPointe
Recognized revenue	0	$ 111		72	$ 321
Deferred revenue	$ 112			$ 112		$ 72
Minimum \| XpresTest \| CDC Program Options and Public Health Services
Unrecognized revenue contract amount			$ 61,000

Potentially Dilutive Securities (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Earnings Per Share Disclosure.
Net loss attributable to XWELL, Inc	$ (4,750)	$ (11,531)	$ (9,258)	$ (22,770)
Basic weighted average shares outstanding	4,818,681	4,173,894	4,394,106	4,170,629
Basic net (loss) per share (in dollars per share)	$ (0.99)	$ (2.76)	$ (2.11)	$ (5.46)
Total number of potentially dilutive securities excluded from the calculation of earnings/(loss) per share attributable to common shareholders	474,695	392,361	474,695	392,361
Both vested and unvested options to purchase an equal number of shares of Common Stock
Earnings Per Share Disclosure.
Total number of potentially dilutive securities excluded from the calculation of earnings/(loss) per share attributable to common shareholders	439,487	377,717	439,487	377,717
Unvested RSUs to issue an equal number of shares of Common Stock
Earnings Per Share Disclosure.
Total number of potentially dilutive securities excluded from the calculation of earnings/(loss) per share attributable to common shareholders	35,208	14,444	35,208	14,444
Warrants to purchase an equal number of shares of Common Stock
Earnings Per Share Disclosure.
Total number of potentially dilutive securities excluded from the calculation of earnings/(loss) per share attributable to common shareholders		200		200

Cash, Cash Equivalents, and Restricted Cash - Summary of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Cash, Cash Equivalents, and Restricted Cash
Cash denominated in United States dollars	$ 1,777	$ 5,726
Cash denominated in currency other than United States dollars	2,305	2,395
Restricted cash	751	751
Credit and debit card receivables	283	316
Total cash, cash equivalents and restricted cash	$ 5,116	$ 9,188	$ 5,578	$ 19,789

Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Cash, Cash Equivalents, and Restricted Cash
Deposits in excess of FDIC limits	$ 2,048	$ 4,195
Amount of cash in overseas accounts	$ 2,305	$ 2,395

Other current assets - Schedule of Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Other current assets
Prepaid expenses	$ 1,814	$ 894
Other	91	55
Total other current assets	$ 1,905	$ 949

Intangible Assets - Schedule of Finite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 3,826	$ 3,840
Accumulated Amortization	(2,719)	(2,487)
Net Carrying Amount	1,107	1,353
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	200	200
Accumulated Amortization	(23)	(6)
Net Carrying Amount	177	194
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,012	1,012
Accumulated Amortization	(416)	(341)
Net Carrying Amount	596	671
Software
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	2,584	2,593
Accumulated Amortization	(2,257)	(2,120)
Net Carrying Amount	327	473
Licenses
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	30	35
Accumulated Amortization	(23)	(20)
Net Carrying Amount	$ 7	$ 15

Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Intangible Assets
Impairment of intangible assets	$ 0	$ 2,758	$ 0	$ 2,758
Amortization expense - intangibles	$ 78	$ 396	$ 237	$ 1,155

Intangible Assets - Amortization Maturity (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
Remaining 2024	$ 79
2025	303
2026	228
2027	122
2028	122
Thereafter	253
Total	$ 1,107	$ 1,353

Accrued expenses and other current liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Accrued expenses and other current liabilities
Litigation accrual		$ 449
Accrued compensation	$ 1,596	2,098
Tax-related liabilities	488	501
Common area maintenance accruals	439	8
Accounts payable accruals	110	913
Gift certificates	507	509
Credit card processing fees	6	8
Other miscellaneous accruals	546	482
Total accrued expenses and other current liabilities	$ 3,692	$ 4,968

Acquisition of Naples Wax, LLC (Details) - USD ($) $ in Thousands		3 Months Ended			9 Months Ended
	Sep. 12, 2023	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Acquisition of Naples Wax, LLC
Impairment of goodwill		$ 0		$ 4,024	$ 0	$ 4,024
Naples Wax LLC
Acquisition of Naples Wax, LLC
Consideration paid	$ 1,624
Aggregate purchase price paid in cash	1,574		$ 14
Consideration held back to cover potential indemnification claims	$ 50
Consideration held back term	6 months
Operating expenses					36
Impairment of goodwill					$ 0
Percentage of acquired ownership interests	100.00%
Deductible goodwill acquired	$ 1,371

Leases - Supplemental Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Leases
Operating cash flows from operating leases	$ (2,585)	$ (2,668)
Leased assets obtained in exchange for new and modified operating lease liabilities	$ 3,091	$ 174

Leases - Future Minimum Commitments (Details) $ in Thousands	Sep. 30, 2024 USD ($)
Leases
Remaining 2024	$ 914
2025	2,982
2026	2,184
2027	2,058
2028	1,676
2029	1,421
Thereafter	2,915
Total future lease payments	14,150
Less: interest expense at incremental borrowing rate	(2,534)
Net present value of lease liabilities	$ 11,616

Leases - Other Assumptions and Pertinent Information (Details)	Sep. 30, 2024
Leases
Weighted average remaining lease term (years):	5 years 9 months
Weighted average discount rate used to determine present value of operating lease liability:	7.10%

Leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Leases
Cash paid for minimum annual rental	$ 433	$ 503	$ 1,202	$ 1,762
Variable lease payments	$ 330	$ 302	$ 1,030	$ 1,013

Other Assets - Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Other Assets
Equity investments	$ 42	$ 50
Lease deposits	1,589	1,556
Other	201	236
Other assets	$ 1,832	$ 1,842

Stockholders' Equity - August 2024 Registered Direct Offering (Details) - USD ($) $ in Thousands		9 Months Ended
	Aug. 06, 2024	Sep. 30, 2024
Warrants [Line Items]
Gross proceeds		$ 1,355
August 2024 Registered Direct Offering
Warrants [Line Items]
Aggregate shares	652,705
Estimated fees and expenses	$ 100
Gross proceeds	$ 1,400

Stockholders' Equity - Stockholders' Equity - Stock-based Compensation (Details) $ in Thousands		1 Months Ended	3 Months Ended		9 Months Ended
	Oct. 04, 2022 shares	Sep. 30, 2020 shares	Sep. 30, 2024 USD ($) installment shares	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) installment shares	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Stockholders Equity [Line Items]
Total stock-based compensation \| $			$ 232	$ 594	$ 818	$ 1,832
Employee Stock Option
Stockholders Equity [Line Items]
Unrecognized stock-based compensation \| $			$ 368		$ 368		$ 1,319
Equity incentive plan 2020
Stockholders Equity [Line Items]
Number of shares authorized (in shares)	625,000	250,000
Number of additional shares authorized (in shares)	375,000
Equity incentive plan 2020 \| Employee Stock Option
Stockholders Equity [Line Items]
Number of equal quarterly vesting installments \| installment			4		4
Options expiration period (in years)					10 years
Equity incentive plan 2020 \| RSUs
Stockholders Equity [Line Items]
Award vesting period (in years)					1 year
Equity incentive plan 2020 \| Maximum
Stockholders Equity [Line Items]
Number of shares available for issuance (in shares)			117,775		117,775
XpresTest 2020 Plan
Stockholders Equity [Line Items]
Number of shares authorized (in shares)		200
Percentage of shares authorized for issuance (in %)		20.00%
Unrecognized stock-based compensation \| $			$ 27	$ 120	$ 27	$ 120

Stockholders' Equity - Variables Used in Estimating Fair Value of Stock Options (Details) - $ / shares	9 Months Ended
	Sep. 30, 2024	Aug. 06, 2024
Stockholders Equity [Line Items]
Share price of the Company's Common Stock on the grant date:		$ 2.26
Employee Stock Option
Stockholders Equity [Line Items]
Expected volatility:	121.04%
Expected dividend yield:	0.00%
Expected term:	6 years 3 months 25 days
Minimum \| Employee Stock Option
Stockholders Equity [Line Items]
Share price of the Company's Common Stock on the grant date:	$ 1.50
Exercise price:	$ 1.50
Annual average risk-free rate:	4.05%
Maximum \| Employee Stock Option
Stockholders Equity [Line Items]
Share price of the Company's Common Stock on the grant date:	$ 1.80
Exercise price:	$ 1.80
Annual average risk-free rate:	4.14%

Stockholders' Equity - Stock Options and RSU Activity (Details)	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Stockholders Equity [Line Items]
No. of options, Outstanding, Beginning balance \| shares	341,205
No. of options, Granted \| shares	180,000
No. of options, Exercised/Vested \| shares	(3,000)
No. of options, Forfeited \| shares	(29,439)
No. of options, Expired \| shares	(49,279)
No. of options, Outstanding, Ending balance \| shares	439,487
No. of options, Exercisable \| shares	375,421
Weighted average grant date fair value, Beginning balance	$ 26.85
Weighted average grant date fair value, Granted	1.55
Weighted average grant date fair value, Exercised/Vested	1.50
Weighted average grant date fair value, Forfeited	17.47
Weighted average grant date fair value, Expired	31.18
Weighted average grant date fair value, Ending balance	16.80
Weighted average grant date fair value, Exercisable	15.68
Exercise price range, Exercised/Vested	$ 1.50
RSUs
Stockholders Equity [Line Items]
RSUs and RSAs Outstanding, Beginning \| shares	11,944
No. of RSUs and RSAs, Granted \| shares	30,000
No. of RSUs and RSAs, Exercised/Vested \| shares	(4,236)
No. of RSUs and RSAs, Forfeited \| shares	(2,500)
RSUs and RSAs Outstanding, Ending \| shares	35,208
Weighted average grant date fair value, RSUs and RSAs, Beginning	$ 6.08
Weighted average grant date fair value, RSUs and RSAs granted	1.80
Weighted average grant date fair value, RSUs and RSAs exercised/vested	5.67
Weighted average grant date fair value, RSUs and RSAs forfeited	5.09
Weighted average grant date fair value, RSUs and RSAs, Ending	$ 2.61
XpresTest RSAs
Stockholders Equity [Line Items]
RSUs and RSAs Outstanding, Beginning \| shares	5
RSUs and RSAs Outstanding, Ending \| shares	5
Weighted average grant date fair value, RSUs and RSAs, Beginning	$ 47,570
Weighted average grant date fair value, RSUs and RSAs, Ending	47,570
Minimum
Stockholders Equity [Line Items]
Exercise price range, Outstanding, Beginning balance	4.60
Exercise price range, Granted	1.50
Exercise price range, Forfeited	1.50
Exercise price range, Expired	8.00
Exercise price range, Outstanding, Ending balance	1.50
Exercise price range, Exercisable	1.50
Maximum
Stockholders Equity [Line Items]
Exercise price range, Outstanding, Beginning balance	49,200
Exercise price range, Granted	1.80
Exercise price range, Forfeited	34.40
Exercise price range, Expired	49,200
Exercise price range, Outstanding, Ending balance	7,080
Exercise price range, Exercisable	$ 7,080

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Sep. 30, 2024
Income Taxes
Annual effective tax rate for continuing operations (in %)	0.00%	0.00%
Income tax expense (benefit) attributable to state taxing jurisdictions	$ 0	$ 0

Commitments and Contingencies (Details) - USD ($) $ / shares in Units, $ in Thousands	May 09, 2022	Sep. 30, 2024	Aug. 06, 2024	Jun. 30, 2024	Dec. 31, 2023
Loss Contingencies [Line Items]
Settlement agreement, number of shares reserved for issuance			416,000
Fair market value			$ 2.26
OTG Management PHL B
Loss Contingencies [Line Items]
Sublease contractual term (in years)	12 years
CPC Pain & Wellness SPV, LLC
Loss Contingencies [Line Items]
Stake ownership				9.42%
Accrued expenses and other current liabilities
Loss Contingencies [Line Items]
Estimated litigation liability - current		$ 0			$ 449
Minimum \| OTG Management PHL B
Loss Contingencies [Line Items]
Loss contingency damages sought	$ 864
Maximum \| OTG Management PHL B
Loss Contingencies [Line Items]
Loss contingency damages sought	$ 2,250

Segment Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
Segment Information (Details) $ in Thousands	Sep. 30, 2024 USD ($) location	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) location segment	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Revenue
Total revenue	$ 8,422	$ 7,468	$ 26,430	$ 22,706
Operating (loss)
Total operating (loss)	(4,769)	(12,089)	(9,040)	(23,101)
Total Depreciation & Amortization	252	590	705	1,770
Total Impairment/loss on disposal of assets	152	8,411	823	8,429
Total capital expenditures	1,587	1,760	1,587	1,760
Assets
Total long-lived Assets	12,965		12,965		$ 10,838
Total assets	33,785		$ 33,785		38,993
Number of operating segments \| segment			4
Number of reportable segments \| segment			4
XpresSpa
Revenue
Total revenue	4,711	4,955	$ 13,870	14,682
Operating (loss)
Total operating (loss)	(2,438)	(2,947)	(6,620)	(8,901)
Total Depreciation & Amortization	187	421	473	1,275
Total Impairment/loss on disposal of assets	137	1,460	156	1,468
Total capital expenditures	861	1,596	861	1,596
Assets
Total long-lived Assets	8,173		8,173		8,268
Total assets	18,933		18,933		18,453
XpresTest
Revenue
Total revenue	3,144	2,322	10,630	7,541
Operating (loss)
Total operating (loss)	1,138	(5,267)	4,450	(5,067)
Total Depreciation & Amortization	16	91	72	260
Total Impairment/loss on disposal of assets		5,338		5,348
Total capital expenditures	44	80	44	80
Assets
Total long-lived Assets	26		26		92
Total assets	1,395		1,395		2,408
Naples Wax
Revenue
Total revenue	429		1,594
Operating (loss)
Total operating (loss)	(66)		(177)
Total Depreciation & Amortization	34		97
Total capital expenditures	668		668
Assets
Total long-lived Assets	4,441		4,441		1,371
Total assets	$ 5,573		$ 5,573		2,951
Number of High- Performing Locations \| location	3		3
Treat
Revenue
Total revenue	$ 138	191	$ 336	483
Operating (loss)
Total operating (loss)	81	(1,585)	39	(2,389)
Total Depreciation & Amortization	1	66	20	198
Total Impairment/loss on disposal of assets	15	1,613	667	1,613
Total capital expenditures	4	56	4	56
Assets
Total long-lived Assets	27		27		669
Total assets	328		328		848
Corporate and Other
Operating (loss)
Total operating (loss)	(3,484)	(2,290)	(6,732)	(6,744)
Total Depreciation & Amortization	14	12	43	37
Total capital expenditures	10	$ 28	10	$ 28
Assets
Total long-lived Assets	298		298		438
Total assets	$ 7,556		$ 7,556		$ 14,333

XWELL (NASDAQ:XWEL)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

XWELL (NASDAQ:XWEL)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

XWEL XWELL Inc

News XWELL Inc

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

XWEL XWELL Inc

News XWELL Inc

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen